<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS157695</article-id><article-id pub-id-type="doi">10.1101/2022.11.23.517669</article-id><article-id pub-id-type="archive">PPR576168</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">2</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Poly ADP-Ribose Signaling is Dysregulated in Huntington Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6103-5835</contrib-id><name><surname>Maiuri</surname><given-names>Tamara</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1884-5760</contrib-id><name><surname>Bazan</surname><given-names>Carlos Barba</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1134-391X</contrib-id><name><surname>Harding</surname><given-names>Rachel J.</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9805-8037</contrib-id><name><surname>Begeja</surname><given-names>Nola</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7241-4902</contrib-id><name><surname>Kam</surname><given-names>Tae-In</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1650-4273</contrib-id><name><surname>Byrne</surname><given-names>Lauren M.</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5567-7938</contrib-id><name><surname>Rodrigues</surname><given-names>Filipe B.</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7677-127X</contrib-id><name><surname>Warner</surname><given-names>Monica M.</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7699-9680</contrib-id><name><surname>Neuman</surname><given-names>Kaitlyn</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8192-6590</contrib-id><name><surname>Mansoor</surname><given-names>Muqtasid</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3722-4609</contrib-id><name><surname>Badiee</surname><given-names>Mohsen</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0001-0000-7951-9662</contrib-id><name><surname>Dasovich</surname><given-names>Morgan</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7715-2489</contrib-id><name><surname>Wang</surname><given-names>Keona</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4573-9514</contrib-id><name><surname>Thompson</surname><given-names>Leslie M</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5569-4036</contrib-id><name><surname>Leung</surname><given-names>Anthony K. L.</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4795-2856</contrib-id><name><surname>Andres</surname><given-names>Sara N.</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6921-7887</contrib-id><name><surname>Wild</surname><given-names>Edward J.</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6459-0893</contrib-id><name><surname>Dawson</surname><given-names>Ted M.</given-names></name><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2915-3970</contrib-id><name><surname>Dawson</surname><given-names>Valina L.</given-names></name><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4971-3250</contrib-id><name><surname>Arrowsmith</surname><given-names>Cheryl H.</given-names></name><xref ref-type="aff" rid="A12">12</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2542-6641</contrib-id><name><surname>Truant</surname><given-names>Ray</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Biochemistry and Biomedical Sciences, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02fa3aq29</institution-id><institution>McMaster University</institution></institution-wrap>, <city>Hamilton</city>, <state>ON</state><postal-code>L8S 3Z5</postal-code>, <country country="CA">Canada</country></aff><aff id="A2"><label>2</label>Structural Genomics Consortium, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dbr7087</institution-id><institution>University of Toronto</institution></institution-wrap>, <city>Toronto</city>, <state>ON</state><postal-code>M5G 1L7</postal-code>, <country country="CA">Canada</country>; Department of Pharmacology and Toxicology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dbr7087</institution-id><institution>University of Toronto</institution></institution-wrap>, <city>Toronto</city>, <state>ON</state><postal-code>M5S 1A8</postal-code>, <country country="CA">Canada</country></aff><aff id="A3"><label>3</label>Neurodegeneration and Stem Cell Programs, Institute for Cell Engineering, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Johns Hopkins University</institution></institution-wrap> School of Medicine, <city>Baltimore</city>, <state>MD</state><postal-code>21205</postal-code>, <country country="US">USA</country>; Department of Neurology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Johns Hopkins University</institution></institution-wrap> School of Medicine, <city>Baltimore</city>, <state>MD</state><postal-code>21205</postal-code>, <country country="US">USA</country></aff><aff id="A4"><label>4</label>UCL Huntington Disease Centre, UCL Queen Square Institute of Neurology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jx3x895</institution-id><institution>University College London</institution></institution-wrap>, <city>London</city>, <country country="GB">UK</country></aff><aff id="A5"><label>5</label>Department of Biochemistry and Biomedical Sciences, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02fa3aq29</institution-id><institution>McMaster University</institution></institution-wrap>, <city>Hamilton</city>, <state>ON</state><postal-code>L8S 3Z5</postal-code>, <country country="CA">Canada</country>; Michael G. DeGroote Institute for Infectious Disease Research, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02fa3aq29</institution-id><institution>McMaster University</institution></institution-wrap>, <city>Hamilton</city>, <state>ON</state>, <country country="CA">Canada</country></aff><aff id="A6"><label>6</label>Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Johns Hopkins University</institution></institution-wrap>, <city>Baltimore</city>, <state>MD</state><postal-code>21205</postal-code>, <country country="US">USA</country></aff><aff id="A7"><label>7</label>Department of Neurobiology and Behavior, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gyf1771</institution-id><institution>University of California</institution></institution-wrap>, <city>Irvine</city>, <state>CA</state><postal-code>92697</postal-code>, <country country="US">USA</country></aff><aff id="A8"><label>8</label>Department of Neurobiology and Behavior, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gyf1771</institution-id><institution>University of California</institution></institution-wrap>, <city>Irvine</city>, <state>CA</state><postal-code>92697</postal-code>, <country country="US">USA</country>; Department of Psychiatry and Human Behavior, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gyf1771</institution-id><institution>University of California</institution></institution-wrap>, <city>Irvine</city>, <state>CA</state><postal-code>92868</postal-code>, <country country="US">USA</country></aff><aff id="A9"><label>9</label>Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Johns Hopkins University</institution></institution-wrap>, <city>Baltimore</city>, <state>MD</state><postal-code>21205</postal-code>, <country country="US">USA</country>; Department of Molecular Biology and Genetics, Department of Genetic Medicine, Department of Oncology, School of Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Johns Hopkins University</institution></institution-wrap>, <city>Baltimore</city>, <state>MD</state><postal-code>21205</postal-code>, <country country="US">USA</country></aff><aff id="A10"><label>10</label>Neurodegeneration and Stem Cell Programs, Institute for Cell Engineering, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Johns Hopkins University</institution></institution-wrap> School of Medicine, <city>Baltimore</city>, <state>MD</state><postal-code>21205</postal-code>, <country country="US">USA</country>; Department of Neurology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Johns Hopkins University</institution></institution-wrap> School of Medicine, <city>Baltimore</city>, <state>MD</state><postal-code>21205</postal-code>, <country country="US">USA</country>; Department of Pharmacology and Molecular Sciences, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Johns Hopkins University</institution></institution-wrap> School of Medicine, <city>Baltimore</city>, <state>MD</state><postal-code>21205</postal-code>, <country country="US">USA</country>; Solomon H. Snyder Department of Neuroscience, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Johns Hopkins University</institution></institution-wrap> School of Medicine, <city>Baltimore</city>, <state>MD</state><postal-code>21205</postal-code>, <country country="US">USA</country></aff><aff id="A11"><label>11</label>Neurodegeneration and Stem Cell Programs, Institute for Cell Engineering, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Johns Hopkins University</institution></institution-wrap> School of Medicine, <city>Baltimore</city>, <state>MD</state><postal-code>21205</postal-code>, <country country="US">USA</country>; Department of Neurology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Johns Hopkins University</institution></institution-wrap> School of Medicine, <city>Baltimore</city>, <state>MD</state><postal-code>21205</postal-code>, <country country="US">USA</country>; Department of Physiology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Johns Hopkins University</institution></institution-wrap> School of Medicine, <city>Baltimore</city>, <state>MD</state><postal-code>21205</postal-code>, <country country="US">USA</country>; Solomon H. Snyder Department of Neuroscience, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Johns Hopkins University</institution></institution-wrap> School of Medicine, <city>Baltimore</city>, <state>MD</state><postal-code>21205</postal-code>, <country country="US">USA</country></aff><aff id="A12"><label>12</label>Structural Genomics Consortium, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dbr7087</institution-id><institution>University of Toronto</institution></institution-wrap>, <city>Toronto</city>, <state>ON</state><postal-code>M5G 1L7</postal-code>, <country country="CA">Canada</country>; Princess Margaret Cancer Centre and Department of Medical Biophysics, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dbr7087</institution-id><institution>University of Toronto</institution></institution-wrap>, <city>Toronto</city>, <state>ON</state><postal-code>M5G 1L7</postal-code>, <country country="CA">Canada</country></aff><author-notes><corresp id="CR1">
<label>*</label><bold>Materials and correspondence</bold>: All correspondence and requests for materials should be sent to: Tamara Maiuri, HSC4N53, 1200 Main Street West, Hamilton, Ontario, Canada L8N3Z5, 905-525-9140 ex22672, <email>maiurit@mcmaster.ca</email>; Ray Truant, HSC4N54, 1200 Main Street West, Hamilton, Ontario, Canada L8N3Z5, 905-525-9140 ex22450, <email>truantr@mcmaster.ca</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>27</day><month>11</month><year>2022</year></pub-date><pub-date pub-type="preprint"><day>24</day><month>11</month><year>2022</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">Huntington disease (HD) is a genetic neurodegenerative disease caused by CAG expansion in the <italic>Huntingtin (HTT)</italic> gene, translating to an expanded polyglutamine tract in the huntingtin (HTT) protein. Age at disease onset correlates to CAG repeat length but varies by decades between individuals with identical repeat lengths. Genome-wide association studies link HD modification to DNA repair and mitochondrial health pathways. Clinical studies show elevated DNA damage in HD, even at the premanifest stage. A major DNA repair node influencing neurodegenerative disease is the PARP pathway. Accumulation of poly ADP-ribose (PAR) has been implicated in Alzheimer and Parkinson diseases, as well as cerebellar ataxia. We report that HD mutation carriers have lower cerebrospinal fluid PAR levels than healthy controls, starting at the premanifest stage. Human HD iPSC-derived neurons and patient-derived fibroblasts have diminished PAR response in the context of elevated DNA damage. We have defined a PAR-binding motif in huntingtin, detected huntingtin complexed with PARylated proteins in human cells during stress, and localized huntingtin to mitotic chromosomes upon inhibition of PAR degradation. Direct huntingtin PAR binding was measured by fluorescence polarization and visualized by atomic force microscopy at the single molecule level. While wild type and mutant huntingtin did not differ in their PAR binding ability, purified wild type huntingtin protein increased <italic>in vitro</italic> PARP1 activity while mutant huntingtin did not. These results provide insight into an early molecular mechanism of HD, suggesting possible targets for the design of early preventive therapies.</p></abstract><kwd-group><kwd>Huntington disease</kwd><kwd>huntingtin</kwd><kwd>poly ADP-ribose</kwd><kwd>DNA repair</kwd><kwd>neurodegenerative disease</kwd><kwd>human</kwd><kwd>cerebrospinal fluid</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">Huntington disease (HD) is an autosomal dominant genetic neurodegenerative disease caused by a CAG expansion in exon1 of the <italic>Huntingtin (HTT)</italic> gene, which translates to an expanded polyglutamine tract in the huntingtin (HTT) protein. HD is characterized by psychiatric, cognitive, and motor disturbances for which some symptom management treatments, but no disease-modifying therapies, exist. Age at disease onset is negatively correlated with CAG expansion length, and onset typically occurs in the third or fourth decades of life [<xref ref-type="bibr" rid="R1">1</xref>]. However, age at disease onset in individuals with the same CAG length can vary by decades [<xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R3">3</xref>]. This variability has an inherited component [<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R5">5</xref>], suggesting that other genes may act as modifiers of disease onset. Genome-wide association studies (GWAS) have primarily implicated DNA repair and maintenance pathways as such modifiers [<xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R7">7</xref>]. While the pathogenic mechanisms have yet to be elucidated, single nucleotide polymorphisms in DNA repair genes that affect somatic instability of the huntingtin locus have been linked to age at onset [<xref ref-type="bibr" rid="R8">8</xref>–<xref ref-type="bibr" rid="R10">10</xref>], and elevated levels of DNA damage in HD patient-derived samples have been reported [<xref ref-type="bibr" rid="R11">11</xref>–<xref ref-type="bibr" rid="R22">22</xref>].</p><p id="P3">The connection between DNA repair and neurodegeneration is not unique to Huntington disease, and has been described for Alzheimer disease [<xref ref-type="bibr" rid="R23">23</xref>], Parkinson disease [<xref ref-type="bibr" rid="R24">24</xref>], spinocerebellar ataxias [<xref ref-type="bibr" rid="R25">25</xref>,<xref ref-type="bibr" rid="R26">26</xref>], and amyotrophic lateral sclerosis [<xref ref-type="bibr" rid="R27">27</xref>,<xref ref-type="bibr" rid="R28">28</xref>]. Inherited mutations in a number of DNA repair genes cause neurodegenerative disorders [<xref ref-type="bibr" rid="R29">29</xref>–<xref ref-type="bibr" rid="R33">33</xref>], and of the nine neurodegenerative genetic polyglutamine diseases, seven of the causative proteins have been implicated in the DNA damage response [<xref ref-type="bibr" rid="R34">34</xref>]. Huntingtin forms a transcription-coupled DNA repair complex with RNA polymerase II subunit A, polynucleotide kinase-phosphatase (PNKP), and ataxin-3, and mutant huntingtin interferes with this function [<xref ref-type="bibr" rid="R21">21</xref>,<xref ref-type="bibr" rid="R22">22</xref>]. We have previously reported that huntingtin interacts with ataxia-telangiectasia mutated (ATM), and that ATM kinase activity is required for huntingtin-chromatin interaction in response to oxidative stress [<xref ref-type="bibr" rid="R12">12</xref>]. We have more recently identified a similar relationship between ATM and ataxin-1, the protein product of the <italic>ATXN1</italic> gene mutated in spinocerebellar ataxia 1 [<xref ref-type="bibr" rid="R35">35</xref>]. ATM signaling is also dysregulated in HD models and brain tissue [<xref ref-type="bibr" rid="R11">11</xref>], placing it as a DNA damage repair node in neurodegenerative diseases.</p><p id="P4">Another such node of DNA damage repair is PARP signaling, which has been implicated in Alzheimer, Parkinson, and Huntington diseases (reviewed in [<xref ref-type="bibr" rid="R36">36</xref>]) as well as progressive cerebellar ataxia [<xref ref-type="bibr" rid="R32">32</xref>] and amyotrophic lateral sclerosis (ALS) [<xref ref-type="bibr" rid="R28">28</xref>]. Of the 17 members of the PARP family, PARP1 and PARP2 are critical in the DNA damage response, with PARP1 accounting for 80-90% of DNA repair-related activity [<xref ref-type="bibr" rid="R37">37</xref>,<xref ref-type="bibr" rid="R38">38</xref>]. Upon activation by DNA breaks, PARP1 and PARP2 use ADP-ribose units from nicotinamide adenine dinucleotide (NAD<sup>+</sup>) as building blocks to generate poly ADP-ribose (PAR) chains of varying length and branching structure. PAR chains act as recruitment scaffolds for DNA repair proteins [<xref ref-type="bibr" rid="R39">39</xref>–<xref ref-type="bibr" rid="R41">41</xref>]. Part of the repair process involves PAR degradation by poly ADP-ribose glycohydrolase (PARG), which is required to allow DNA repair proteins access to the damaged DNA [<xref ref-type="bibr" rid="R42">42</xref>], and to recycle ATP precursor metabolites [<xref ref-type="bibr" rid="R43">43</xref>,<xref ref-type="bibr" rid="R44">44</xref>].</p><p id="P5">Excessive PAR polymerization, or lack of degradation, results in NAD<sup>+</sup> depletion, energy crisis, and cell death by necrosis [<xref ref-type="bibr" rid="R45">45</xref>]. Overactivation of PARP1 can also trigger the non-apoptotic programmed cell death termed parthanatos [<xref ref-type="bibr" rid="R46">46</xref>], which is particularly important in neurodegenerative disease [<xref ref-type="bibr" rid="R47">47</xref>]. Hyper-PARylation has been implicated in several neurodegenerative diseases [<xref ref-type="bibr" rid="R32">32</xref>,<xref ref-type="bibr" rid="R48">48</xref>–<xref ref-type="bibr" rid="R50">50</xref>], including HD [<xref ref-type="bibr" rid="R51">51</xref>–<xref ref-type="bibr" rid="R53">53</xref>].</p><p id="P6">Here, we show that PAR signaling is dysregulated in HD patient cells and cerebrospinal fluid (CSF). Analysis of HD mutation carrier CSF samples revealed lower total PAR levels than control samples, a difference evident from the premanifest stage. Elevated DNA damage levels in HD iPSC-derived neurons and patient-derived fibroblasts were not reflected by increased PAR levels, and HD patient-derived cells had lower PARP1/2 inhibitor IC50 than control cells. Consistent with this, wild type purified recombinant huntingtin increased autoPARylation of purified recombinant PARP1 in an <italic>in vitro</italic> assay, while mutant huntingtin was deficient in this capacity. We detected endogenous huntingtin complexed with PARylated proteins in human retinal epithelial cells, which prompted analysis of the huntingtin structure and identification of a PAR-binding motif. Fluorescence polarization and atomic force microscopy revealed a direct interaction between huntingtin protein and PAR polymers. While PAR binding by wild type or mutant huntingtin did not differ, mutant huntingtin was not able to stimulate PARP1 activity while wild type protein demonstrated this activity. This provides a possible mechanistic link to the observations made in patient cells and CSF. In addition to uncovering a role for the normal huntingtin protein in PAR biology, these results provide insight into the very early molecular mechanism of HD pathogenesis, to potentially reveal targets for an early preventive therapy for HD.</p></sec><sec id="S2" sec-type="results"><title>Results</title><sec id="S3"><title>The PAR response is deficient in HD patient-derived samples</title><p id="P7">Elevated PAR levels have been observed in human samples from multiple neurodegenerative diseases [<xref ref-type="bibr" rid="R32">32</xref>,<xref ref-type="bibr" rid="R48">48</xref>–<xref ref-type="bibr" rid="R50">50</xref>]. Although PARP1 inhibition was reported to be neuroprotective in a mouse model of HD [<xref ref-type="bibr" rid="R51">51</xref>,<xref ref-type="bibr" rid="R52">52</xref>], and elevated PARP1 levels were observed in the neurons and glia of the caudate nucleus from HD patients [<xref ref-type="bibr" rid="R53">53</xref>], it remains unknown whether hyper-PARylation contributes to HD pathology. As cancer drugs targeting PARP1 are under consideration for repurposing to treat neurodegenerative diseases [<xref ref-type="bibr" rid="R54">54</xref>,<xref ref-type="bibr" rid="R55">55</xref>], investigation of their potential for HD is imperative. To test patient-relevant CNS-specific samples, we measured PAR levels in CSF from HD patients compared to controls. Samples were obtained from the HD-CSF study, an 80-participant cross-sectional study of HD mutation carriers and matched healthy controls [<xref ref-type="bibr" rid="R56">56</xref>,<xref ref-type="bibr" rid="R57">57</xref>] (see <xref ref-type="sec" rid="S">methods section</xref> for details). In contrast to similar analyses in Parkinson's disease [<xref ref-type="bibr" rid="R50">50</xref>], we found that PAR levels were significantly lower in the CSF from both pre-manifest (p = 0.0001) and manifest HD patients (p = 0.0004) compared to controls, and that gene status had a large effect on PAR levels in CSF (η<sup>2</sup><sub>p</sub> = 0.35) (<xref ref-type="fig" rid="F1">Fig 1</xref>). PAR levels in the CSF of HD mutation carriers did not correlate with CSF mutant huntingtin or neurofilament light chain (NfL) levels, both of which were shown to correlate with disease severity in HD patients [<xref ref-type="bibr" rid="R56">56</xref>,<xref ref-type="bibr" rid="R57">57</xref>] (<xref ref-type="supplementary-material" rid="SD1">Fig S1</xref>). In addition, CSF PAR levels in HD mutation carriers did not correlate with clinical measures of disease progression such as disease burden score, total functional capacity, or total motor score (<xref ref-type="supplementary-material" rid="SD1">Fig S2</xref>). Yet, lower PAR levels correlated with the presence of the mutant huntingtin allele.</p><p id="P8">The reduced PAR levels in the CSF of premanifest and manifest HD patients were unexpected given the numerous reports of increased DNA damage in HD patient samples and models. For example, iPSC-derived neurons bearing the HD mutation have increased DNA breaks and expression of damage markers phospho-ATM, γH2AX, and phospho-p53 [<xref ref-type="bibr" rid="R21">21</xref>,<xref ref-type="bibr" rid="R22">22</xref>]. We therefore aimed to determine whether this increase in DNA damage was reflected by elevated PAR levels. As shown in <xref ref-type="fig" rid="F2">Fig 2A</xref>, we found no corresponding increase in PAR levels in HD iPSC-derived neurons. In fact, neurons bearing a juvenile onset HD allele (Q77) had lower PAR levels than control, consistent with the observations made in patient CSF.</p><p id="P9">We and others have previously reported elevated levels of DNA damage in fibroblasts derived from HD patients compared to controls [<xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R18">18</xref>,<xref ref-type="bibr" rid="R20">20</xref>]. We therefore measured DNA damage and PAR levels in control cells bearing wild type alleles that encode 21 or 18 polyglutamine residues (TruHD-Q21Q18), and HD patient-derived cells carrying one expanded allele (TruHD-Q43Q17), or two expanded alleles (TruHD-Q50Q40), TruHD cells [<xref ref-type="bibr" rid="R58">58</xref>]. We employed Repair Assisted Damage Detection (RADD) [<xref ref-type="bibr" rid="R59">59</xref>] to measure DNA breaks and PAR levels in the same cells. RADD directly detects DNA damage using DNA processing enzymes to detect and modify sites of DNA damage for a subsequent gap filling fluorescent labeling reaction. Like HD iPSC-derived neurons, hTERT-immortalized HD patient-derived fibroblasts did not exhibit the increase in PAR levels expected to occur in the context of elevated DNA damage (<xref ref-type="fig" rid="F2">Fig 2B</xref>). This was the case under conditions of oxidative stress, which we have previously shown to be associated with elevated DNA damage in these cells by comet assay [<xref ref-type="bibr" rid="R12">12</xref>], as well as under basal conditions, in which increased damage was also detected by RADD (<xref ref-type="fig" rid="F2">Fig 2B</xref>). To ensure that the PAR detection assay is within the dynamic range and the signal has not reached saturation, we quantified PAR signal intensity in a KBrO<sub>3</sub> dose response experiment. As shown in <xref ref-type="supplementary-material" rid="SD1">Fig S3</xref>, a treatment of 100 mM KBrO<sub>3</sub> for 30 minutes produces a PAR response within the dynamic range. Further, HD cells exhibited lower PAR levels than wild type cells at the other KBrO<sub>3</sub> doses.</p><p id="P10">Since hTERT expression is equal across the immortalized fibroblast lines [<xref ref-type="bibr" rid="R58">58</xref>], and similar results were obtained in iPSC-derived neurons and patient CSF, we did not anticipate a confounding effect of hTERT overexpression. This was confirmed by repeating the experiment in the primary fibroblasts from which the TruHD lines were derived (<xref ref-type="supplementary-material" rid="SD1">Fig S4</xref>). It should be noted that although we did not observe the expected elevated PAR phenotype in HD patient-derived cells, PAR was generated in response to oxidative stress, indicating that they are not fully deficient in this capacity (<xref ref-type="fig" rid="F2">Fig 2B</xref>). To further characterize this PAR signaling deficiency, we correlated per-nucleus RADD and PAR signal intensities for control and HD patient-derived cells and found them to be correlated (<xref ref-type="supplementary-material" rid="SD1">Fig S5</xref>). As expected, the correlation increased with KBrO<sub>3</sub> treatment, however HD cells had lower Spearman r values than wild type cells under both conditions. This suggests that the PAR response is not fully deficient but is subdued in the HD context, as would be expected for a late onset, slowly progressing disease. Together, the reduced PAR levels in HD patient CSF, and lack of elevated PAR in the context of elevated DNA damage in HD neurons and patient-derived fibroblasts, suggest that the PAR response is deficient in HD patients.</p><p id="P11">We next examined the mechanisms of PAR production and degradation in TruHD cells. During the DNA repair process, PAR is rapidly generated by PARP1 and PARP2, and degraded by enzymes such as PARG. To determine whether the lower than expected PAR levels were due to increased PARG activity, we performed dose response experiments to measure the PARG inhibitor PDD00017273 IC50 [<xref ref-type="bibr" rid="R60">60</xref>] and found no difference between HD and control cells (<xref ref-type="fig" rid="F3">Fig 3A</xref>). In contrast, dose response experiments with the PARP1/2 inhibitor veliparib revealed lower veliparib IC50 in HD cells compared to controls (TruHD-Q21Q18 IC50 = 140 nM; TruHD-Q43Q17 IC50 = 60 nM; TruHD-Q50Q40 IC50 = 60 nM) (<xref ref-type="fig" rid="F3">Fig 3B</xref>). This is despite similar levels of PARP1, PARP2, and PARG across cell lines (<xref ref-type="supplementary-material" rid="SD1">Fig S6A</xref>) and equal PARP1 chromatin retention upon oxidative stress (<xref ref-type="supplementary-material" rid="SD1">Fig S6B</xref>). To ensure that the lowered IC50 is not an artifact specific to veliparib, we repeated the experiment with talazoparib, which acts by a different mechanism than veliparib [<xref ref-type="bibr" rid="R61">61</xref>,<xref ref-type="bibr" rid="R62">62</xref>], and found a reduced IC50 in HD cells (<xref ref-type="supplementary-material" rid="SD1">Fig S6C</xref>), as was seen with veliparib. To address whether the reduced PARP inhibitor IC50 values were a direct effect of huntingtin, we tested the autoPARylation activity of purified recombinant PARP1 in the presence of purified recombinant HTT-HAP40 Q23 or HTT-HAP40 Q54. As shown in <xref ref-type="fig" rid="F3">Fig 3C</xref>, wild type huntingtin stimulated PARP1 activity in a dose-dependent manner, while mutant huntingtin had no effect. This provides a possible mechanistic link to the reduced PARP inhibitor IC50 values, and subdued PAR response observed in HD patient-derived fibroblasts, as well as the reduced PAR levels in HD iPSC-derived neurons and CSF from HD patients.</p></sec><sec id="S4"><title>Huntingtin interacts with PARylated proteins</title><p id="P12">Mutations associated with progressive cerebellar ataxia with oculomotor apraxia type 1 (AOA1) result in reduced expression of the scaffolding protein XRCC1, causing persistent unrepaired DNA damage and concomitant prolonged PARP1 activity [<xref ref-type="bibr" rid="R32">32</xref>]. Since PAR binding is important for the scaffolding function of XRCC1 in DNA repair complex formation [<xref ref-type="bibr" rid="R63">63</xref>], we sought to determine whether huntingtin could also bind PAR.</p><p id="P13">We first interrogated the results of a mass spectrometry study identifying proteins that interact with huntingtin under conditions of oxidative stress (<xref ref-type="supplementary-material" rid="SD3">Table S1</xref>). The list of huntingtin interactors was compared to a compiled list of PARylated proteins from three independently generated datasets (<xref ref-type="supplementary-material" rid="SD1">Fig S7</xref>) [<xref ref-type="bibr" rid="R64">64</xref>–<xref ref-type="bibr" rid="R66">66</xref>]. As shown in <xref ref-type="fig" rid="F4">Figure 4</xref>, 122 of the 298 (41%) huntingtin-interacting proteins were also found in a database of PARylated proteins. Fisher's test returned a significance of 2.1 x 10<sup>-81</sup>. Thus, a significant proportion of huntingtin-interacting proteins are reported to be modified by PAR (<xref ref-type="supplementary-material" rid="SD4">Table S2</xref>).</p><p id="P14">We next asked whether huntingtin exists in complex with PARylated proteins in cells. Since fibroblasts do not produce sufficient protein for immunoprecipitation analyses, we turned to RPE1 cells, which are hTERT-immortalized and therefore retain DNA repair pathway function. As expected, PAR levels were increased in RPE1 cells treated with hydrogen peroxide (<xref ref-type="fig" rid="F4">Fig 4B</xref>). Furthermore, PARylated proteins were enriched in huntingtin immunoprecipitates upon oxidative stress as shown by western blot analysis. This is consistent with the high degree of overlap between datasets of huntingtin-interacting proteins and PARylated proteins.</p><p id="P15">To further investigate the relationship between huntingtin and PAR in human cells, we examined the subcellular localization of endogenous huntingtin upon manipulation of PAR production and degradation. While endogenous huntingtin localization in interphase cells was similar across conditions, we found that in mitotic cells treated with PARG inhibitor, huntingtin phosphorylated at residues S13 and S16 localized strongly to condensed mitotic chromosomes (<xref ref-type="supplementary-material" rid="SD1">Fig S8</xref> and <xref ref-type="supplementary-material" rid="SD2">Supplementary video 1</xref>). This staining pattern is strikingly similar to that of PAR itself during mitosis [<xref ref-type="bibr" rid="R67">67</xref>,<xref ref-type="bibr" rid="R68">68</xref>], and provides further evidence that huntingtin binds PAR in cells. In contrast, upon inhibition of PARP1/2 activity, huntingtin localized primarily to the mitotic spindle poles (<xref ref-type="fig" rid="F4">Fig 4C</xref>), as we and others have seen previously in untreated cells [<xref ref-type="bibr" rid="R69">69</xref>,<xref ref-type="bibr" rid="R70">70</xref>]. Thus, detection of huntingtin-PAR complexes by immunoprecipitation in cell lysates, and by immunofluorescence in intact cells, suggests that normal huntingtin may play a role in PAR biology, and raises the possibility that huntingtin may directly bind PAR.</p></sec><sec id="S5"><title>Huntingtin contains a PAR-binding motif and directly binds PAR</title><p id="P16">We examined the huntingtin sequence for potential PAR-binding motifs (PBMs) according to consensus sequences derived by others [<xref ref-type="bibr" rid="R64">64</xref>,<xref ref-type="bibr" rid="R71">71</xref>] and found five putative PBMs (<xref ref-type="fig" rid="F5">Fig 5A</xref>). While huntingtin putative PBMs did not match the consensus with 100% similarity, their consensus fitting was comparable to those from previously validated PAR-binding proteins including DNA dependent protein kinase catalytic subunit (DNA-PK) [<xref ref-type="bibr" rid="R71">71</xref>] and 60 kD SS-A/Ro ribonucleoprotein [<xref ref-type="bibr" rid="R72">72</xref>].</p><p id="P17">To test these putative motifs, we performed PAR overlay assays with peptides representing the putative PBMs (<xref ref-type="fig" rid="F5">Fig 5B</xref>). PBM-3 displayed strong PAR-binding activity, which was ablated by mutation of the critical arginine residues. Multiple sequence alignment of human huntingtin and several orthologous species revealed a high degree of evolutionary conservation of PBM-3 and the surrounding sequences (<xref ref-type="supplementary-material" rid="SD1">Fig S9</xref>). Mapping of this sequence on the cryo-EM structure of huntingtin [<xref ref-type="bibr" rid="R73">73</xref>] shows that PBM-3 is solvent accessible (<xref ref-type="fig" rid="F5">Fig 5C</xref>), situated on the bridge domain at the interface of the N-HEAT domain with a surface area of ~890 Å<sup>2</sup>. The motif spans a connecting loop region in this HEAT repeat in addition to a small section of each of the two flanking α-helices. The positively charged K1790, R1795 and R1796 residues are surface exposed in this model of the structure, indicating how they might interact with negatively charged PAR molecules.</p><p id="P18">We then asked whether the huntingtin PBM-3 bears resemblance to the PBM from the structurally similar [<xref ref-type="bibr" rid="R74">74</xref>] and functionally related [<xref ref-type="bibr" rid="R12">12</xref>] protein, ATM. Similar to ATM, the PAR-binding motif of huntingtin is a surface-exposed helix-turn-helix within a HEAT repeat (<xref ref-type="supplementary-material" rid="SD1">Fig S10</xref>). These results suggest that huntingtin PBM-3 is a <italic>bona fide</italic> PAR-binding motif, and that at least some of the interactions detected by immunoprecipitation and mass spectrometry (<xref ref-type="fig" rid="F4">Fig 4</xref> and Table 1) could be direct.</p><p id="P19">To determine whether huntingtin directly interacts with PAR, we tested purified full-length huntingtin protein and PAR linear polymer in a fluorescence polarization assay. As shown in <xref ref-type="fig" rid="F6">Fig 6A</xref>, huntingtin binds long (26-mer) PAR chains, in preference to shorter (11-mer) substrates. This is similar to the substrate length specificity of other PAR binding proteins [<xref ref-type="bibr" rid="R75">75</xref>]. It should be noted that while these results support a direct interaction, the technical constraints of the experiment preclude saturation of the binding curve and therefore determination of binding kinetics and specificity. At 10 μM protein, HTT-HAP40 Q23 exhibited lower binding than the positive control PAR-binding protein HUWE1, but higher binding than the negative control non-PAR-binding protein USP5 (<xref ref-type="supplementary-material" rid="SD1">Fig S11</xref>). We next tested the PAR binding ability of different huntingtin subdomain constructs [<xref ref-type="bibr" rid="R76">76</xref>], and found that a construct comprising the N-HEAT and Bridge domains, which contains PBM-3, binds 26-mer PAR, while the C-HEAT domain (in complex with HAP40) does not (<xref ref-type="fig" rid="F6">Fig 6B</xref>). We did not detect a significant difference in PAR binding between wild type and mutant huntingtin, nor upon deletion of the exon 1 domain in this assay (<xref ref-type="fig" rid="F6">Fig 6B</xref>). Thus, a difference in PAR binding does not explain the differential effect that wild type and mutant huntingtin have on PARP1 activity <italic>in vitro</italic> (<xref ref-type="fig" rid="F3">Fig 3C</xref>). These results suggest that huntingtin can directly bind linear PAR chains of at least 26 ADP-ribose units in length, and that binding may be mediated through PBM-3.</p><p id="P20">In order to test whether huntingtin may directly bind PAR chains of various sizes and branching structures, we included purified huntingtin protein in <italic>in vitro</italic> PARP1 reactions, and visualized the reactions by atomic force microscopy at the single molecule level. In the absence of huntingtin, we observed auto-PARylated PARP1 structures consistent with previous reports [<xref ref-type="bibr" rid="R77">77</xref>–<xref ref-type="bibr" rid="R79">79</xref>] (<xref ref-type="fig" rid="F6">Fig 6C</xref>). In contrast, the presence of huntingtin protein in the PARP1 reactions resulted in large rosette structures consistent with huntingtin protein bound to PAR chains (<xref ref-type="fig" rid="F6">Fig 6C</xref>). While visualization of the PARP1 reaction in the presence of huntingtin may give insight into the increased PARP1 autoPARylation activity we detected in the presence of wild type huntingtin by western (<xref ref-type="fig" rid="F3">Fig 3C</xref>), differing buffer conditions and mica substrate effects preclude the elucidation of precise mechanism, which is the topic of future studies.</p><p id="P21">Taken together, these results indicate that huntingtin binds directly to PAR chains <italic>in vitro,</italic> which accounts for its interaction with PARylated proteins in cells. This establishes a link between huntingtin and PAR signaling biology. Despite equivalent PAR binding, wild type huntingtin increases <italic>in vitro</italic> PARP1 activity while mutant huntingtin does not. This may explain the reduced PAR levels in HD patient CSF, and the subdued PAR response and reduced PARP inhibitor IC50 values we observed in patient-derived cells.</p></sec></sec><sec id="S6" sec-type="discussion"><title>Discussion</title><p id="P22">The huntingtin protein is a large scaffold that participates in numerous cellular processes [<xref ref-type="bibr" rid="R80">80</xref>]. We have previously defined a role for huntingtin in the response to oxidative DNA damage [<xref ref-type="bibr" rid="R12">12</xref>], and characterized the nuclear/primary cilium localization signal [<xref ref-type="bibr" rid="R81">81</xref>] and nuclear export signals [<xref ref-type="bibr" rid="R82">82</xref>,<xref ref-type="bibr" rid="R83">83</xref>] regulating its translocation from the endoplasmic reticulum, where it is tethered by the N17 domain, to the nucleus [<xref ref-type="bibr" rid="R69">69</xref>,<xref ref-type="bibr" rid="R84">84</xref>,<xref ref-type="bibr" rid="R85">85</xref>]. Here, we define an evolutionarily conserved PAR-binding motif and show that huntingtin interacts with PARylated proteins. <italic>In vitro,</italic> wild type purified recombinant huntingtin increases autoPARylation of purified recombinant PARP1, while mutant huntingtin is deficient in this capacity. This may contribute to the reduced levels of PAR we observed in the CSF from HD patients and the deficient PAR levels seen in HD iPSC-derived neurons and HD patient-derived fibroblasts in the context of elevated DNA damage.</p><p id="P23">We have previously hypothesized [<xref ref-type="bibr" rid="R34">34</xref>,<xref ref-type="bibr" rid="R86">86</xref>] that aberrant mutant huntingtin function in DNA repair plays a role in the elevated levels of DNA damage seen in several HD models and tissues [<xref ref-type="bibr" rid="R11">11</xref>–<xref ref-type="bibr" rid="R22">22</xref>]. The ability of wild type but not mutant huntingtin to stimulate PARP1 autoPARylation activity provides one possible contributing mechanism. We identified and characterized a PAR binding motif within huntingtin, and found that mutant huntingtin PAR binding was not different from that of wild type. This indicates that mutant huntingtin can bind PAR but cannot stimulate its activity the way that wild type huntingtin can.. While the identification of PBM-3 as a structurally and evolutionarily conserved PAR binding motif strongly suggests that it plays a role in huntingtin PAR binding, the data presented do not exclude the possibility that additional contact points contribute to PAR binding, including possibly PBM-1, which is also found in the N-HEAT subdomain and showed weak binding in the PAR overlay assay. We show that huntingtin directly binds PAR through the identification of a defined PAR binding motif, fluorescence polarization and atomic force microscopy, as well as an interactome of over 100 PARylated proteins and huntingtin localization to PAR-coated mitotic chromosomes upon PARG inhibition.</p><p id="P24">Dysregulation of PAR signaling has now been linked to multiple neurodegenerative diseases. A common theme among these disorders is the hyperactivation of PARP1 in response to oxidative damage. This may also be the case in HD, as evidenced by strong PARP1 expression in the neurons and glia of caudate nucleus from affected HD patients [<xref ref-type="bibr" rid="R53">53</xref>], and by the beneficial effect of PARP1 inhibition in the R6/2 mouse model [<xref ref-type="bibr" rid="R51">51</xref>,<xref ref-type="bibr" rid="R52">52</xref>]. In contrast, we detected lower PAR levels in HD patient CSF and reduced PARP1/2 inhibitor IC50 in fibroblasts from HD patients. The decreased PAR levels we detected in the CSF from HD patients, an anomaly by comparison to similar studies in different neurodegenerative diseases [<xref ref-type="bibr" rid="R32">32</xref>,<xref ref-type="bibr" rid="R48">48</xref>–<xref ref-type="bibr" rid="R50">50</xref>], nonetheless reflect dysregulated PAR signaling in HD. This may parallel the paradoxical PARP inhibitor and PARG inhibitor cancer treatment options [<xref ref-type="bibr" rid="R87">87</xref>], which show that tipping the balance in either direction is detrimental to cancer cells. Static measurements of hypo- and hyper-PARylation may not reflect the dynamic nature of PAR metabolism, but may instead indicate PAR signaling dysregulation in HD. While CSF PAR levels did not correlate with disease measures, the robust reduction in PAR, even in premanifest patients, provides clinically relevant evidence for a role of PAR signaling dysregulation in the early stages of disease. Although we also observed lower than expected PAR levels in iPSC-derived neurons, the important caveat is that CSF PAR is not intraneuronal PAR. The clinical data from CSF may only indicate that there is an abnormal PAR dynamic process, hence an impaired ability to repair DNA, as seen clinically by others as early as premanifest HD [<xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R14">14</xref>].</p><p id="P25">It is interesting to speculate on why PAR levels in the CSF are lower in HD mutation carriers while there is no difference in HD patient-derived fibroblast intracellular levels. This could reflect differences between systemic nervous system fluids versus skin-derived cells grown in a dish, whereby cell culture conditions require a minimum PAR level for cell proliferation. Basal PAR levels were in fact lower in iPSC-derived cultured, non-dividing neurons representing the more severe juvenile HD case (Q77), consistent with lower PAR levels in CSF from HD patients. The ELISA method used to measure CSF PAR levels recognizes both PARylated proteins and free PAR released by brain cells during waste clearance.</p><p id="P26">The fact that PAR levels did not correlate with biomarker levels or clinical measures of disease likely reflects the transient and fluctuating nature of PAR, meaning that it may not be useful as a biomarker of disease state. This is also true of other disease-related molecules such as inflammatory markers [<xref ref-type="bibr" rid="R88">88</xref>] that are linked to pathology but do not have optimal kinetics for biomonitoring. Further, where PAR may be relevant to regionally specific pathology, its level in CSF is not specific to a particular brain region. Therefore, any regional specific changes could be diluted by more general fluctuations. We speculate that dysregulation of PAR signaling in HD may have beneficial secondary consequences, such as the reduced cancer rates seen in CAG expansion carriers [<xref ref-type="bibr" rid="R89">89</xref>], which could possibly be related to reduced PARP1/2 activity. This could in turn contribute to the apparent evolutionary advantage of longer CAG repeat lengths, which are not in equilibrium in human populations, but are subject to mutational bias towards expansion [<xref ref-type="bibr" rid="R90">90</xref>].</p><p id="P27">An interaction between HD and cancer via PARP1/2 activity may provide opportunity for the repurposing of currently available cancer drugs targeting this pathway. Future studies will look at different classes of FDA-approved PARP1 inhibitor drugs as some trap PARP1 on DNA, and some can cross the blood brain barrier while others cannot [<xref ref-type="bibr" rid="R54">54</xref>,<xref ref-type="bibr" rid="R55">55</xref>]. Interrogation of large banks of HD patient data [<xref ref-type="bibr" rid="R91">91</xref>] may make it possible to determine changes in disease progression associated with administration of such drugs, while the emerging development of new PARP and PARG inhibitors may hold promise for HD and neurodegenerative diseases at large.</p></sec><sec id="S7" sec-type="materials | methods"><title>Materials and Methods</title><sec id="S8"><title>Antibodies and reagents</title><p id="P28">All reagents were from MilliporeSigma unless otherwise stated. Veliparib (ABT-888) was from Selleckchem. PARG inhibitor (PDD00017273) was from AdipoGen Lifesciences. Antibodies are listed in <xref ref-type="supplementary-material" rid="SD1">Supplementary methods</xref>. Mica and specimen supports were from Ted Pella Inc.</p></sec><sec id="S9"><title>Human CSF samples</title><p id="P29">CSF samples were collected as part of the HD-CSF study, a prospective single-site study with standardized longitudinal collection of CSF, blood and phenotypic data (online protocol: 10.5522/04/11828448.v1). The cohort included manifest and premanifest HD mutation carriers as well as healthy controls who were age and gender matched to the entire HD mutation carrier group (<xref ref-type="supplementary-material" rid="SD1">Fig S12</xref>). All samples were de-identified prior to use in this study. In summary, lumbar punctures were performed after 12-hour fasting, in the early morning, and samples were processed within 30 minutes after the collection. Processed samples were aliquoted and stored at -80°C until shipment on dry ice for PAR quantification.</p></sec><sec id="S10"><title>Measurement of CSF analytes</title><p id="P30">PAR quantification was performed using an in-house ELISA as previously described [<xref ref-type="bibr" rid="R50">50</xref>]. NfL, mHTT, and Hemoglobin were quantified using the Simoa® Neurology 4-plex B kits (Item 103345, Quanterix, Lexington MA, USA, at UCL), the SMCxPro (2B7/MW1, in-house at Evotec) and ELISA (E88-134, Bethyl Laboratories; at Evotec), respectively, as described previously (57).</p></sec><sec id="S11"><title>Cell culture and treatments</title><p id="P31">TruHD cells[<xref ref-type="bibr" rid="R58">58</xref>] were cultured in MEM (Life Technologies #10370) with 15% fetal bovine serum (FBS; Life Technologies) and 1X GlutaMAX (Life Technologies #35050) and grown at 37°C with 5% CO<sub>2</sub> and 5-8% O<sub>2</sub>. ST<italic>Hdh</italic> cells[<xref ref-type="bibr" rid="R92">92</xref>] were cultured in DMEM (Life Technologies #11995) with 10% FBS and grown at 33°C with 5% CO<sub>2</sub>. RPE1 cells (American Type Culture Collection) were cultured in 1:1 DMEM/Nutrient Mixture F-12 (DMEM/F12; Life Technologies #11330) with 10% FBS and 0.01% hygromycin and grown at 37°C with 5% CO<sub>2</sub> and 5-8% O<sub>2</sub>. Induction of DNA damage with H<sub>2</sub>O<sub>2</sub> or KBrO<sub>3</sub> was done in Hank's balanced salt solution (HBSS) or phosphate-buffered saline (PBS), at the concentrations and durations indicated in figure legends.</p></sec><sec id="S12"><title>Neuronal differentiation of iPSCs</title><p id="P32">HD iPSCs were differentiated as previously described [<xref ref-type="bibr" rid="R21">21</xref>,<xref ref-type="bibr" rid="R93">93</xref>]. All samples were de-identified prior to use in this study.</p></sec><sec id="S13"><title>Measurement of PAR levels in cells</title><p id="P33">Cells were seeded in 8-well ibiTreat μ-Slides (Ibidi) to ~95% confluence. For KBrO<sub>3</sub> dose response experiments, cells were seeded in glass-bottom 96-well plates (CellVis). After the indicated treatments, cells were stained and imaged as described in <xref ref-type="supplementary-material" rid="SD1">Supplementary methods</xref>.</p></sec><sec id="S14"><title>Repair assisted damage detection (RADD)</title><p id="P34">Cells were seeded in 8-well ibiTreat μ-Slides (Ibidi) or Mod3D chambers [<xref ref-type="bibr" rid="R94">94</xref>] to ~95% confluence. Cells were washed with PBS then incubated with PBS containing 0 mM or 100 mM KBrO<sub>3</sub> for 30 min. RADD was performed as described [<xref ref-type="bibr" rid="R59">59</xref>] and <xref ref-type="supplementary-material" rid="SD1">Supplementary methods</xref>. Cells were imaged in PBS using the 20× objective on the EVOS FL Auto 2 widefield microscope. Nuclei were identified as primary objects in CellProfiler [<xref ref-type="bibr" rid="R95">95</xref>] using the Hoechst staining, then pixel intensity of the RADD and PAR staining within nuclei was calculated and the mean intensity recorded for each image. Eighteen images per well were captured, representing &gt;500 cells per experiment.</p></sec><sec id="S15"><title>Inhibitor dose response experiments</title><p id="P35">PARP1/2 and PARG activities were measured using the method described by James et al [<xref ref-type="bibr" rid="R60">60</xref>] and in the <xref ref-type="supplementary-material" rid="SD1">Supplementary methods</xref>. IC50 values were calculated using GraphPad Prism Version 9.4.1. Means were assessed by Brown-Forsythe and Welch ANOVA tests followed by Dunnett's T3 multiple comparisons test with individual variances computed for each comparison.</p></sec><sec id="S16"><title>Immunofluorescence</title><p id="P36">To measure chromatin retention of PARP1, TruHD cells were grown in CellCarrier-96 Ultra Microplates (Perkin Elmer) and treated for 30 min with 100 mM KBrO<sub>3</sub> dissolved in PBS containing Ca<sup>2+</sup> and Mg<sup>2+</sup>. Soluble proteins were extracted with cold 0.2% Triton X-100 in PBS containing Ca<sup>2+</sup> and Mg<sup>2+</sup> for 2 min on ice prior to staining as described in <xref ref-type="supplementary-material" rid="SD1">Supplementary methods</xref>.</p><p id="P37">For imaging of mitotic cells, RPE1 cells were stained as described in <xref ref-type="supplementary-material" rid="SD1">Supplementary methods</xref>.</p></sec><sec id="S17"><title>Cell lysis and western analysis</title><p id="P38">For measurement of protein levels by western, cells were lysed using radioimmunoprecipitation assay buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1mM EDTA) with protease and phosphatase inhibitors (Roche) and protein levels were measured with the Qubit Protein Broad Range (BR) Assay (ThermoFisher). Westerns were performed and quantified as described in <xref ref-type="supplementary-material" rid="SD1">Supplementary methods</xref>.</p></sec><sec id="S18"><title>Purification of huntingtin-interacting proteins</title><p id="P39">ST<italic>Hdh</italic><sup>Q7/Q7</sup> mouse striatal precursor cells were treated with either HBSS, HBSS containing 60 μg/mL methyl methanesulfonate (MMS) for 20 min, or HBSS containing 100 μM H<sub>2</sub>O<sub>2</sub> for 1 hour. Proteins were purified as described in <xref ref-type="supplementary-material" rid="SD1">Supplementary methods</xref>.</p></sec><sec id="S19"><title>Mass spectrometry and protein identification</title><p id="P40">Samples were trypsin-digested, desalted on C18 column, and LC-MS/MS performed on the Q Exactive HF-X mass spectrometer (SPARC BioCentre, Toronto, Canada). For database searching, tandem mass spectra were extracted by Proteome Discoverer. MS/MS samples were analyzed using Sequest (XCorr Only) as described in <xref ref-type="supplementary-material" rid="SD1">Supplementary methods</xref>.</p></sec><sec id="S20"><title>PAR overlay assay</title><p id="P41">Peptides were ordered from Genscript (see sequences in <xref ref-type="supplementary-material" rid="SD1">Supplementary methods</xref>) and diluted to 0.5 mg/mL in PBS. One microgram of each peptide was slot-blotted onto nitrocellulose membrane. Membranes were fixed in 2.5% glutaraldehyde/PBS for 30 min then washed with TBS-T (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Tween-20), followed by incubation with 0.2 μM PAR polymer (Trevigen) in TBS-T for 30 min, three washes with excess TBS-T, and blocking with 5% milk in TBS-T for 15 min. PAR was detected using MABE1016 (1:1000 in TBS-T + 5% milk) and anti-rabbit-HRP (1:50000 in TBS-T + 5% milk). Membranes were then incubated with 0.5% Ponceau in 3% acetic acid for 10 min and washed in dH<sub>2</sub>O.</p></sec><sec id="S21"><title>Protein purification</title><p id="P42">Huntingtin and HAP40 constructs used in this study have been described previously[<xref ref-type="bibr" rid="R96">96</xref>] and in the <xref ref-type="supplementary-material" rid="SD1">Supplementary methods</xref>, and are available through Addgene.</p></sec><sec id="S22"><title>Fluorescence polarization</title><p id="P43">FAM-labeled 11-mer and 26-mer PAR were produced as described [<xref ref-type="bibr" rid="R97">97</xref>]. Fluorescence polarization reactions were carried out in 20 mM HEPES pH 7.4, 50 mM KCl, 2.5% glycerol, 1 mM TCEP, 2 mM MgCl<sub>2</sub>, and 0.005% Tween-20 with a final concentration of 25 nM PAR substrate and 10 μM protein in a total reaction volume of 10 μL. Reactions were analysed using a Synergy H4 plate reader (Biotek) and data analysed using Graphpad Prism (version 9.4.1).</p></sec><sec id="S23"><title><italic>In vitro</italic> PARP1 reaction and atomic force microscopy</title><p id="P44">For analysis by western blot, 10 fmol recombinant PARP1 was incubated in a 15-uL reaction (5 mM NAD+, 1X activated DNA, 50 mM Tris HCl pH 7.75, 50 mM NaCl) with the indicated amounts of recombinant HTT-HAP40 for 2 hours at 30°C. Reactions were separated by SDS-PAGE and immunoblotted with MABE1016 pan-ADP-ribose detection reagent. Signal intensities were quantified using ImageJ. For analysis by AFM, 35 nM PARP1 was incubated with 5 μg/mL sonicated salmon sperm DNA (Abcam ab229278) in deposition buffer (12.5 mM HEPES pH 8, 12.5 mM KCl, 1 mM DTT) in the the presence of 100 μM NAD<sup>+</sup> and 10 mM MgCl<sub>2</sub> with or without 11.5 nM HTT-HAP40 at 37°C for 30 min. Samples were diluted 10-fold in deposition buffer containing 3 mM MgCl<sub>2</sub> and 10 μL deposited on freshly cleaved mica for 5 min before rinsing with HPLC-grade water and drying under nitrogen stream. AFM images were captured in air on a Bruker Dimension iCon (Bruker, Santa-Barbara, CA, USA) in soft tapping mode with ScanAsyst-Air tip (Bruker). In this experiment, continuous force–distance curves were recorded at 256 x 256 pixels at line rate 0.996 Hz, and the tip was oscillated in the vertical direction with an amplitude of 100–300 nm and at low frequency (1–2 kHz). Images were created using Nanoscope Analysis version 2.0 (Bruker Corporation).</p></sec><sec id="S24"><title>Statistical analysis</title><sec id="S25"><title>Human CSF analyses</title><p id="P45">Statistical analysis was performed using STATA MP Version 18. P values of &lt;0.05 were considered significant. CSF PAR values were assessed for normality and subsequently log transformed. We assessed potential confounders including age, gender, blood contamination and time in the freezer. Hemoglobin was used as an indicator of blood contamination. There was an association between CSF PAR and storage time in the freezer (<xref ref-type="supplementary-material" rid="SD1">Fig S12</xref>), therefore we included storage time as a covariate in all analyses. Group comparisons were assessed using multiple regression adding storage time as a covariate followed by post-estimation Wald tests (also known as a Wald Chi-Square test, used to assess the significance of the coefficients in a regression model). Bonferroni correction was used to adjust for multiple comparisons. Correlations were assessed using Pearson's partial correlation.</p></sec><sec id="S26"><title>Experiment-based analyses</title><p id="P46">All data are represented as mean ± SEM with 3 independent experiments unless otherwise stated in the figure legends. Statistical analysis was performed using GraphPad Prism Version 9.4.1 and described for each experiment in figure legends. Differences among multiple means were assessed by ANOVA followed by Tukey's post hoc test. Non-normally distributed data were analyzed with nonparametric test (Mann-Whitney test). Assessments with P &lt; 0.05 were considered significant. Eta squared values were used to determine gene status effect size, with 0.01 representing a small effect, 0.06 representing a moderate effect, and 0.14 representing a large effect[<xref ref-type="bibr" rid="R98">98</xref>].</p></sec></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplemental figures and methods</label><media xlink:href="EMS157695-supplement-Supplemental_figures_and_methods.pdf" mimetype="application" mime-subtype="pdf" id="d21aAcEbB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>Supplemental movie 1</label><media xlink:href="EMS157695-supplement-Supplemental_movie_1.mp4" mimetype="video" mime-subtype="mp4" id="d21aAcEcB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD3"><label>Table S1</label><media xlink:href="EMS157695-supplement-Table_S1.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d21aAcEdB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD4"><label>Table S2</label><media xlink:href="EMS157695-supplement-Table_S2.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d21aAcEeB" position="anchor"/></supplementary-material></sec></body><back><ack id="S"><title>Acknowledgements</title><p>The authors gratefully acknowledge the participation of HD patients and families, without whom this work could not be completed. This research was supported by the Canadian Institutes of Health Research Project Grant (MOP-119391) and the Krembil Foundation (RT), the Huntington Disease Society of America Berman Topper Career Development Fellowship and HD Human Biology Project (TM), Canadian Institutes of Health Research Project Grant (PJT180258 to SNA).</p><p>This work was also supported, in part, by a grant from the NIH R37 NS067525. T.M.D. is the Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases. Support also included grants from the NIH to AKLL (R01GM104135), MD (T32GM080189), and MB (T32-CA009110), and from NINDS to LMT (R35 NS116872).</p><p>EJW reports research grants from Medical Research Council (MR/M008592/1), CHDI Foundation, European Huntington Disease Network, and F. Hoffmann-La Roche Ltd. The HD-CSF study was undertaken at the Leonard Wolfson Experimental Neurology Centre, University College London, supported by the National Institute for Health Research UCL Hospitals Biomedical Research Centre.</p><p>LMB is funded by the Medical research council (MR/W026686/1).</p><p>The Structural Genomics Consortium is a registered charity (no: 1097737) that receives funds from Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Genome Canada through Ontario Genomics Institute [OGI-196], EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking [EUbOPEN grant 875510], Janssen, Merck KGaA (aka EMD in Canada and US), Pfizer and Takeda.</p></ack><fn-group><fn id="FN1" fn-type="con"><p id="P47"><bold>Author contributions</bold></p><p id="P48">TM conceived the project, designed and conducted experiments, analyzed and interpreted data, supervised the project and wrote the manuscript. CBB, RJH, LMB, FBR, and MD designed and conducted experiments, analyzed and interpreted data and contributed to drafting and editing the manuscript. NB, TK, MMW, KN, MM, MB, and KW conducted experiments and analyzed data. AKLL, SNA, EJW, TMD, VLD, CHA, LMT and RT supervised the work, analyzed and interpreted data and contributed to drafting and editing the manuscript.</p></fn><fn id="FN2" fn-type="conflict"><p id="P49"><bold>Conflict-of-interest statement</bold></p><p id="P50">EJW reports consultancy / advisory board memberships with Annexon, Remix Therapeutics, Hoffman La Roche Ltd, Ionis Pharmaceuticals, PTC Therapeutics, Takeda, Teitur Trophics, Triplet Therapeutics and Vico Therapeutics. All honoraria for these consultancies were paid through the offices of UCL Consultants Ltd., a wholly owned subsidiary of University College London. FBR is a Medpace UK Ltd employee and was a University College London employee during the conduct of this study. FBR has provided consultancy services to G.L.G. and F. Hoffmann-La Roche Ltd. LMB currently holds consultancy contracts with Annexon Biosciences, Remix Therapeutics, and LoQus23 Therapeutics Ltd via UCL Consultants Ltd. RT has past consultancy with Novartis AG, PTC Therapeutics and Mitokinin LLC.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J-M</given-names></name><name><surname>Ramos</surname><given-names>EM</given-names></name><name><surname>Lee</surname><given-names>J-H</given-names></name><name><surname>Gillis</surname><given-names>T</given-names></name><name><surname>Mysore</surname><given-names>JS</given-names></name><name><surname>Hayden</surname><given-names>MR</given-names></name><etal/></person-group><article-title>CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion</article-title><source>Neurology</source><year>2012</year><volume>78</volume><fpage>690</fpage><lpage>695</lpage><pub-id pub-id-type="pmcid">PMC3306163</pub-id><pub-id pub-id-type="pmid">22323755</pub-id><pub-id pub-id-type="doi">10.1212/WNL.0b013e318249f683</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><collab>Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium</collab><article-title>CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset</article-title><source>Cell</source><year>2019</year><volume>178</volume><fpage>887</fpage><lpage>900</lpage><elocation-id>e14</elocation-id><pub-id pub-id-type="pmcid">PMC6700281</pub-id><pub-id pub-id-type="pmid">31398342</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2019.06.036</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><collab>Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium</collab><article-title>Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease</article-title><source>Cell</source><year>2015</year><volume>162</volume><fpage>516</fpage><lpage>526</lpage><pub-id pub-id-type="pmcid">PMC4524551</pub-id><pub-id pub-id-type="pmid">26232222</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2015.07.003</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Djousse</surname><given-names>L</given-names></name><name><surname>Knowlton</surname><given-names>B</given-names></name><name><surname>Hayden</surname><given-names>M</given-names></name><name><surname>Almqvist</surname><given-names>EW</given-names></name><name><surname>Brinkman</surname><given-names>R</given-names></name><name><surname>Ross</surname><given-names>C</given-names></name><etal/></person-group><article-title>Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease</article-title><source>Am J Med Genet A</source><year>2003</year><volume>119</volume><fpage>279</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">12784292</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wexler</surname><given-names>NS</given-names></name><name><surname>Lorimer</surname><given-names>J</given-names></name><name><surname>Porter</surname><given-names>J</given-names></name><name><surname>Gomez</surname><given-names>F</given-names></name><name><surname>Moskowitz</surname><given-names>C</given-names></name><name><surname>Shackell</surname><given-names>E</given-names></name><etal/></person-group><article-title>Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><fpage>3498</fpage><lpage>3503</lpage><pub-id pub-id-type="pmcid">PMC373491</pub-id><pub-id pub-id-type="pmid">14993615</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0308679101</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bettencourt</surname><given-names>C</given-names></name><name><surname>Hensman-Moss</surname><given-names>D</given-names></name><name><surname>Flower</surname><given-names>M</given-names></name><name><surname>Wiethoff</surname><given-names>S</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Goizet</surname><given-names>C</given-names></name><etal/></person-group><article-title>DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases</article-title><source>Ann Neurol</source><year>2016</year><volume>79</volume><fpage>983</fpage><lpage>990</lpage><pub-id pub-id-type="pmcid">PMC4914895</pub-id><pub-id pub-id-type="pmid">27044000</pub-id><pub-id pub-id-type="doi">10.1002/ana.24656</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moss</surname><given-names>DJH</given-names></name><name><surname>Pardiñas</surname><given-names>AF</given-names></name><name><surname>Langbehn</surname><given-names>D</given-names></name><name><surname>Lo</surname><given-names>K</given-names></name><name><surname>Leavitt</surname><given-names>BR</given-names></name><name><surname>Roos</surname><given-names>R</given-names></name><etal/></person-group><article-title>Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study</article-title><source>Lancet Neurol</source><year>2017</year><volume>16</volume><fpage>701</fpage><lpage>711</lpage><pub-id pub-id-type="pmid">28642124</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciosi</surname><given-names>M</given-names></name><name><surname>Maxwell</surname><given-names>A</given-names></name><name><surname>Cumming</surname><given-names>SA</given-names></name><name><surname>Hensman Moss</surname><given-names>DJ</given-names></name><name><surname>Alshammari</surname><given-names>AM</given-names></name><name><surname>Flower</surname><given-names>MD</given-names></name><etal/></person-group><article-title>A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes</article-title><source>EBioMedicine</source><year>2019</year><volume>48</volume><fpage>568</fpage><lpage>580</lpage><pub-id pub-id-type="pmcid">PMC6838430</pub-id><pub-id pub-id-type="pmid">31607598</pub-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2019.09.020</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goold</surname><given-names>R</given-names></name><name><surname>Flower</surname><given-names>M</given-names></name><name><surname>Moss</surname><given-names>DH</given-names></name><name><surname>Medway</surname><given-names>C</given-names></name><name><surname>Wood-Kaczmar</surname><given-names>A</given-names></name><name><surname>Andre</surname><given-names>R</given-names></name><etal/></person-group><article-title>FAN1 modifies Huntington's disease progression by stabilizing the expanded HTT CAG repeat</article-title><source>Hum Mol Genet</source><year>2019</year><volume>28</volume><fpage>650</fpage><lpage>661</lpage><pub-id pub-id-type="pmcid">PMC6360275</pub-id><pub-id pub-id-type="pmid">30358836</pub-id><pub-id pub-id-type="doi">10.1093/hmg/ddy375</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flower</surname><given-names>M</given-names></name><name><surname>Lomeikaite</surname><given-names>V</given-names></name><name><surname>Ciosi</surname><given-names>M</given-names></name><name><surname>Cumming</surname><given-names>S</given-names></name><name><surname>Morales</surname><given-names>F</given-names></name><name><surname>Lo</surname><given-names>K</given-names></name><etal/></person-group><article-title>MSH3 modifies somatic instability and disease severity in Huntington's and myotonic dystrophy type 1</article-title><source>Brain</source><year>2019</year><pub-id pub-id-type="pmcid">PMC6598626</pub-id><pub-id pub-id-type="pmid">31216018</pub-id><pub-id pub-id-type="doi">10.1093/brain/awz115</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>X-H</given-names></name><name><surname>Mattis</surname><given-names>VB</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Al-Ramahi</surname><given-names>I</given-names></name><name><surname>van den Berg</surname><given-names>N</given-names></name><name><surname>Fratantoni</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease</article-title><source>Sci Transl Med</source><year>2014</year><volume>6</volume><elocation-id>268ra178</elocation-id><pub-id pub-id-type="pmid">25540325</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maiuri</surname><given-names>T</given-names></name><name><surname>Mocle</surname><given-names>AJ</given-names></name><name><surname>Hung</surname><given-names>CL</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>van Roon-Mom</surname><given-names>WMC</given-names></name><name><surname>Truant</surname><given-names>R</given-names></name></person-group><article-title>Huntingtin is a scaffolding protein in the ATM oxidative DNA damage response complex</article-title><source>Hum Mol Genet</source><year>2017</year><volume>26</volume><fpage>395</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">28017939</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Askeland</surname><given-names>G</given-names></name><name><surname>Dosoudilova</surname><given-names>Z</given-names></name><name><surname>Rodinova</surname><given-names>M</given-names></name><name><surname>Klempir</surname><given-names>J</given-names></name><name><surname>Liskova</surname><given-names>I</given-names></name><name><surname>Kuśnierczyk</surname><given-names>A</given-names></name><etal/></person-group><article-title>Increased nuclear DNA damage precedes mitochondrial dysfunction in peripheral blood mononuclear cells from Huntington's disease patients</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><elocation-id>9817</elocation-id><pub-id pub-id-type="pmcid">PMC6026140</pub-id><pub-id pub-id-type="pmid">29959348</pub-id><pub-id pub-id-type="doi">10.1038/s41598-018-27985-y</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castaldo</surname><given-names>I</given-names></name><name><surname>De Rosa</surname><given-names>M</given-names></name><name><surname>Romano</surname><given-names>A</given-names></name><name><surname>Zuchegna</surname><given-names>C</given-names></name><name><surname>Squitieri</surname><given-names>F</given-names></name><name><surname>Mechelli</surname><given-names>R</given-names></name><etal/></person-group><article-title>DNA damage signatures in peripheral blood cells as biomarkers in prodromal huntington disease</article-title><source>Ann Neurol</source><year>2019</year><volume>85</volume><fpage>296</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">30549309</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scudiero</surname><given-names>DA</given-names></name><name><surname>Meyer</surname><given-names>SA</given-names></name><name><surname>Clatterbuck</surname><given-names>BE</given-names></name><name><surname>Tarone</surname><given-names>RE</given-names></name><name><surname>Robbins</surname><given-names>JH</given-names></name></person-group><article-title>Hypersensitivity to N-methyl-N'-nitro-N-nitrosoguanidine in fibroblasts from patients with Huntington disease, familial dysautonomia, and other primary neuronal degenerations</article-title><source>Proc Natl Acad Sci U S A</source><year>1981</year><volume>78</volume><fpage>6451</fpage><lpage>6455</lpage><pub-id pub-id-type="pmcid">PMC349057</pub-id><pub-id pub-id-type="pmid">6458814</pub-id><pub-id pub-id-type="doi">10.1073/pnas.78.10.6451</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moshell</surname><given-names>AN</given-names></name><name><surname>Tarone</surname><given-names>RE</given-names></name><name><surname>Barrett</surname><given-names>SF</given-names></name><name><surname>Robbins</surname><given-names>JH</given-names></name></person-group><article-title>Radiosensitivity in Huntington's disease: implications for pathogenesis and presymptomatic diagnosis</article-title><source>Lancet</source><year>1980</year><volume>1</volume><fpage>9</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">6101401</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ooi</surname><given-names>J</given-names></name><name><surname>Langley</surname><given-names>SR</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Utami</surname><given-names>KH</given-names></name><name><surname>Sim</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Unbiased Profiling of Isogenic Huntington Disease hPSC-Derived CNS and Peripheral Cells Reveals Strong Cell-Type Specificity of CAG Length Effects</article-title><source>Cell Reports</source><year>2019</year><fpage>2494</fpage><lpage>2508</lpage><elocation-id>e7</elocation-id><pub-id pub-id-type="pmid">30811996</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palminha</surname><given-names>NM</given-names></name><name><surname>Dos Santos Souza</surname><given-names>C</given-names></name><name><surname>Griffin</surname><given-names>J</given-names></name><name><surname>Liao</surname><given-names>C</given-names></name><name><surname>Ferraiuolo</surname><given-names>L</given-names></name><name><surname>El-Khamisy</surname><given-names>SF</given-names></name></person-group><article-title>Defective repair of topoisomerase I induced chromosomal damage in Huntington's disease</article-title><source>Cell Mol Life Sci</source><year>2022</year><volume>79</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="pmcid">PMC8882575</pub-id><pub-id pub-id-type="pmid">35224690</pub-id><pub-id pub-id-type="doi">10.1007/s00018-022-04204-6</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lange</surname><given-names>J</given-names></name><name><surname>Gillham</surname><given-names>O</given-names></name><name><surname>Flower</surname><given-names>M</given-names></name><name><surname>Ging</surname><given-names>H</given-names></name><name><surname>Eaton</surname><given-names>S</given-names></name><name><surname>Kapadia</surname><given-names>S</given-names></name><name><surname>Neueder</surname><given-names>A</given-names></name><name><surname>Duchen</surname><given-names>MR</given-names></name><name><surname>Ferretti</surname><given-names>P</given-names></name><name><surname>Tabrizi</surname><given-names>SJ</given-names></name></person-group><article-title>PolyQ length-dependent metabolic alterations and DNA damage drive human astrocyte dysfunction in Huntington's disease</article-title><source>Prog Neurobiol</source><year>2023</year><elocation-id>102448</elocation-id><pub-id pub-id-type="pmid">37023937</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferlazzo</surname><given-names>ML</given-names></name><name><surname>Sonzogni</surname><given-names>L</given-names></name><name><surname>Granzotto</surname><given-names>A</given-names></name><name><surname>Bodgi</surname><given-names>L</given-names></name><name><surname>Lartin</surname><given-names>O</given-names></name><name><surname>Devic</surname><given-names>C</given-names></name><etal/></person-group><article-title>Mutations of the Huntington's disease protein impact on the ATM-dependent signaling and repair pathways of the radiation-induced DNA double-strand breaks: corrective effect of statins and bisphosphonates</article-title><source>Mol Neurobiol</source><year>2014</year><volume>49</volume><pub-id pub-id-type="pmid">24277524</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Chakraborty</surname><given-names>A</given-names></name><name><surname>Geater</surname><given-names>C</given-names></name><name><surname>Pradhan</surname><given-names>S</given-names></name><name><surname>Gordon</surname><given-names>KL</given-names></name><name><surname>Snowden</surname><given-names>J</given-names></name><etal/></person-group><article-title>Mutant huntingtin impairs PNKP and ATXN3, disrupting DNA repair and transcription</article-title><source>Elife</source><year>2019</year><volume>8</volume><pub-id pub-id-type="pmcid">PMC6529219</pub-id><pub-id pub-id-type="pmid">30994454</pub-id><pub-id pub-id-type="doi">10.7554/eLife.42988</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morozko</surname><given-names>EL</given-names></name><name><surname>Smith-Geater</surname><given-names>C</given-names></name><name><surname>Monteys</surname><given-names>AM</given-names></name><name><surname>Pradhan</surname><given-names>S</given-names></name><name><surname>Lim</surname><given-names>RG</given-names></name><name><surname>Langfelder</surname><given-names>P</given-names></name><etal/></person-group><article-title>PIAS1 modulates striatal transcription, DNA damage repair, and SUMOylation with relevance to Huntington's disease</article-title><source>Proc Natl Acad Sci U S A</source><year>2021</year><volume>118</volume><pub-id pub-id-type="pmcid">PMC7848703</pub-id><pub-id pub-id-type="pmid">33468657</pub-id><pub-id pub-id-type="doi">10.1073/pnas.2021836118</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Kapoor</surname><given-names>A</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Chow</surname><given-names>MJ</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>K</given-names></name><etal/></person-group><article-title>Contributions of DNA Damage to Alzheimer's Disease</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><pub-id pub-id-type="pmcid">PMC7084447</pub-id><pub-id pub-id-type="pmid">32121304</pub-id><pub-id pub-id-type="doi">10.3390/ijms21051666</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Hunt</surname><given-names>CP</given-names></name><name><surname>Sanders</surname><given-names>LH</given-names></name></person-group><article-title>DNA damage and repair in Parkinson's disease: Recent advances and new opportunities</article-title><source>J Neurosci Res</source><year>2020</year><pub-id pub-id-type="pmid">32048327</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massey</surname><given-names>TH</given-names></name><name><surname>Jones</surname><given-names>L</given-names></name></person-group><article-title>The central role of DNA damage and repair in CAG repeat diseases</article-title><source>Dis Model Mech</source><year>2018</year><volume>11</volume><pub-id pub-id-type="pmcid">PMC5818082</pub-id><pub-id pub-id-type="pmid">29419417</pub-id><pub-id pub-id-type="doi">10.1242/dmm.031930</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yau</surname><given-names>WY</given-names></name><name><surname>O'Connor</surname><given-names>E</given-names></name><name><surname>Sullivan</surname><given-names>R</given-names></name><name><surname>Akijian</surname><given-names>L</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name></person-group><article-title>DNA repair in trinucleotide repeat ataxias</article-title><source>FEBS J</source><year>2018</year><volume>285</volume><fpage>3669</fpage><lpage>3682</lpage><pub-id pub-id-type="pmid">30152109</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penndorf</surname><given-names>D</given-names></name><name><surname>Witte</surname><given-names>OW</given-names></name><name><surname>Kretz</surname><given-names>A</given-names></name></person-group><article-title>DNA plasticity and damage in amyotrophic lateral sclerosis</article-title><source>Neural Regeneration Res</source><year>2018</year><volume>13</volume><fpage>173</fpage><lpage>180</lpage><pub-id pub-id-type="pmcid">PMC5879878</pub-id><pub-id pub-id-type="pmid">29557356</pub-id><pub-id pub-id-type="doi">10.4103/1673-5374.226377</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>L</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><etal/></person-group><article-title>C9orf72 functions in the nucleus to regulate DNA damage repair</article-title><source>Cell Death Differ</source><year>2022</year><volume>30</volume><fpage>716</fpage><lpage>730</lpage><pub-id pub-id-type="pmcid">PMC9984389</pub-id><pub-id pub-id-type="pmid">36220889</pub-id><pub-id pub-id-type="doi">10.1038/s41418-022-01074-0</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreira</surname><given-names>MC</given-names></name><name><surname>Barbot</surname><given-names>C</given-names></name><name><surname>Tachi</surname><given-names>N</given-names></name><name><surname>Kozuka</surname><given-names>N</given-names></name><name><surname>Uchida</surname><given-names>E</given-names></name><name><surname>Gibson</surname><given-names>T</given-names></name><etal/></person-group><article-title>The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin</article-title><source>Nat Genet</source><year>2001</year><volume>29</volume><fpage>189</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">11586300</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bras</surname><given-names>J</given-names></name><name><surname>Alonso</surname><given-names>I</given-names></name><name><surname>Barbot</surname><given-names>C</given-names></name><name><surname>Costa</surname><given-names>MM</given-names></name><name><surname>Darwent</surname><given-names>L</given-names></name><name><surname>Orme</surname><given-names>T</given-names></name><etal/></person-group><article-title>Mutations in PNKP cause recessive ataxia with oculomotor apraxia type 4</article-title><source>Am J Hum Genet</source><year>2015</year><volume>96</volume><fpage>474</fpage><lpage>479</lpage><pub-id pub-id-type="pmcid">PMC4375449</pub-id><pub-id pub-id-type="pmid">25728773</pub-id><pub-id pub-id-type="doi">10.1016/j.ajhg.2015.01.005</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takashima</surname><given-names>H</given-names></name><name><surname>Boerkoel</surname><given-names>CF</given-names></name><name><surname>John</surname><given-names>J</given-names></name><name><surname>Saifi</surname><given-names>GM</given-names></name><name><surname>Salih</surname><given-names>MAM</given-names></name><name><surname>Armstrong</surname><given-names>D</given-names></name><etal/></person-group><article-title>Mutation of TDP1, encoding a topoisomerase I–dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy</article-title><source>Nat Genet</source><year>2002</year><volume>32</volume><fpage>267</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">12244316</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoch</surname><given-names>NC</given-names></name><name><surname>Hanzlikova</surname><given-names>H</given-names></name><name><surname>Rulten</surname><given-names>SL</given-names></name><name><surname>Tétreault</surname><given-names>M</given-names></name><name><surname>Komulainen</surname><given-names>E</given-names></name><name><surname>Ju</surname><given-names>L</given-names></name><etal/></person-group><article-title>XRCC1 mutation is associated with PARP1 hyperactivation and cerebellar ataxia</article-title><source>Nature</source><year>2017</year><volume>541</volume><fpage>87</fpage><lpage>91</lpage><pub-id pub-id-type="pmcid">PMC5218588</pub-id><pub-id pub-id-type="pmid">28002403</pub-id><pub-id pub-id-type="doi">10.1038/nature20790</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaspers</surname><given-names>NG</given-names></name><name><surname>Gatti</surname><given-names>RA</given-names></name><name><surname>Baan</surname><given-names>C</given-names></name><name><surname>Linssen</surname><given-names>PC</given-names></name><name><surname>Bootsma</surname><given-names>D</given-names></name></person-group><article-title>Genetic complementation analysis of ataxia telangiectasia and Nijmegen breakage syndrome: a survey of 50 patients</article-title><source>Cytogenet Cell Genet</source><year>1988</year><volume>49</volume><fpage>259</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">3248383</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maiuri</surname><given-names>T</given-names></name><name><surname>Hung</surname><given-names>CLK</given-names></name><name><surname>Suart</surname><given-names>C</given-names></name><name><surname>Begeja</surname><given-names>N</given-names></name><name><surname>Barba-Bazan</surname><given-names>C</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>DNA Repair in Huntington's Disease and Spinocerebellar Ataxias: Somatic Instability and Alternative Hypotheses</article-title><source>J Huntingtons Dis</source><year>2021</year><volume>10</volume><fpage>165</fpage><lpage>173</lpage><pub-id pub-id-type="pmcid">PMC7990435</pub-id><pub-id pub-id-type="pmid">33579859</pub-id><pub-id pub-id-type="doi">10.3233/JHD-200414</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suart</surname><given-names>C</given-names></name><name><surname>Perez</surname><given-names>AM</given-names></name><name><surname>Al-Ramahi</surname><given-names>I</given-names></name><name><surname>Maiuri</surname><given-names>T</given-names></name><name><surname>Botas</surname><given-names>J</given-names></name><name><surname>Truant</surname><given-names>R</given-names></name></person-group><article-title>Spinocerebellar Ataxia Type 1 protein Ataxin-1 is signalled to DNA damage by Ataxia Telangiectasia Mutated kinase</article-title><year>2019</year><elocation-id>701953</elocation-id><pub-id pub-id-type="pmid">33772540</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narne</surname><given-names>P</given-names></name><name><surname>Pandey</surname><given-names>V</given-names></name><name><surname>Simhadri</surname><given-names>PK</given-names></name><name><surname>Phanithi</surname><given-names>PB</given-names></name></person-group><article-title>Poly(ADP-ribose)polymerase-1 hyperactivation in neurodegenerative diseases: The death knell tolls for neurons</article-title><source>Semin Cell Dev Biol</source><year>2017</year><volume>63</volume><fpage>154</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">27867042</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shieh</surname><given-names>WM</given-names></name><name><surname>Ame</surname><given-names>JC</given-names></name><name><surname>Wilson</surname><given-names>MV</given-names></name><name><surname>Wang</surname><given-names>ZQ</given-names></name><name><surname>Koh</surname><given-names>DW</given-names></name><name><surname>Jacobson</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><fpage>30069</fpage><lpage>30072</lpage><pub-id pub-id-type="pmid">9804757</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amé</surname><given-names>JC</given-names></name><name><surname>Rolli</surname><given-names>V</given-names></name><name><surname>Schreiber</surname><given-names>V</given-names></name><name><surname>Niedergang</surname><given-names>C</given-names></name><name><surname>Apiou</surname><given-names>F</given-names></name><name><surname>Decker</surname><given-names>P</given-names></name><etal/></person-group><article-title>PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>17860</fpage><lpage>17868</lpage><pub-id pub-id-type="pmid">10364231</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masson</surname><given-names>M</given-names></name><name><surname>Niedergang</surname><given-names>C</given-names></name><name><surname>Schreiber</surname><given-names>V</given-names></name><name><surname>Muller</surname><given-names>S</given-names></name><name><surname>Menissier-de Murcia</surname><given-names>J</given-names></name><name><surname>de Murcia</surname><given-names>G</given-names></name></person-group><article-title>XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage</article-title><source>Mol Cell Biol</source><year>1998</year><volume>18</volume><fpage>3563</fpage><lpage>3571</lpage><pub-id pub-id-type="pmcid">PMC108937</pub-id><pub-id pub-id-type="pmid">9584196</pub-id><pub-id pub-id-type="doi">10.1128/mcb.18.6.3563</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Khamisy</surname><given-names>SF</given-names></name><name><surname>Masutani</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Caldecott</surname><given-names>KW</given-names></name></person-group><article-title>A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage</article-title><source>Nucleic Acids Res</source><year>2003</year><volume>31</volume><fpage>5526</fpage><lpage>5533</lpage><pub-id pub-id-type="pmcid">PMC206461</pub-id><pub-id pub-id-type="pmid">14500814</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkg761</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamaletdinova</surname><given-names>T</given-names></name><name><surname>Fanaei-Kahrani</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Z-Q</given-names></name></person-group><article-title>The Enigmatic Function of PARP1: From PARylation Activity to PAR Readers</article-title><source>Cells</source><year>2019</year><volume>8</volume><pub-id pub-id-type="pmcid">PMC6953017</pub-id><pub-id pub-id-type="pmid">31842403</pub-id><pub-id pub-id-type="doi">10.3390/cells8121625</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Nakajima</surname><given-names>S</given-names></name><name><surname>Hsieh</surname><given-names>C-L</given-names></name><name><surname>Kanno</surname><given-names>S</given-names></name><name><surname>Masutani</surname><given-names>M</given-names></name><name><surname>Levine</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Damage response of XRCC1 at sites of DNA single strand breaks is regulated by phosphorylation and ubiquitylation after degradation of poly(ADP-ribose)</article-title><source>J Cell Sci</source><year>2013</year><volume>126</volume><fpage>4414</fpage><lpage>4423</lpage><pub-id pub-id-type="pmcid">PMC3784821</pub-id><pub-id pub-id-type="pmid">23868975</pub-id><pub-id pub-id-type="doi">10.1242/jcs.128272</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruta</surname><given-names>H</given-names></name><name><surname>Matsumura</surname><given-names>N</given-names></name><name><surname>Tanuma</surname><given-names>S-I</given-names></name></person-group><article-title>Role of (ADP-ribose)nCatabolism in DNA Repair</article-title><source>Biochem Biophys Res Commun</source><year>1997</year><volume>236</volume><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">9240422</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oei</surname><given-names>SL</given-names></name><name><surname>Ziegler</surname><given-names>M</given-names></name></person-group><article-title>ATP for the DNA Ligation Step in Base Excision Repair Is Generated from Poly(ADP-ribose)</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>23234</fpage><lpage>23239</lpage><pub-id pub-id-type="pmid">10930429</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morales</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Fattah</surname><given-names>FJ</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Bey</surname><given-names>EA</given-names></name><name><surname>Patel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases</article-title><source>Crit Rev Eukaryot Gene Expr</source><year>2014</year><volume>24</volume><fpage>15</fpage><lpage>28</lpage><pub-id pub-id-type="pmcid">PMC4806654</pub-id><pub-id pub-id-type="pmid">24579667</pub-id><pub-id pub-id-type="doi">10.1615/critreveukaryotgeneexpr.2013006875</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fatokun</surname><given-names>AA</given-names></name><name><surname>Dawson</surname><given-names>VL</given-names></name><name><surname>Dawson</surname><given-names>TM</given-names></name></person-group><article-title>Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities</article-title><source>Br J Pharmacol</source><year>2014</year><volume>171</volume><fpage>2000</fpage><lpage>2016</lpage><pub-id pub-id-type="pmcid">PMC3976618</pub-id><pub-id pub-id-type="pmid">24684389</pub-id><pub-id pub-id-type="doi">10.1111/bph.12416</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Kam</surname><given-names>T-I</given-names></name><name><surname>Dawson</surname><given-names>TM</given-names></name><name><surname>Dawson</surname><given-names>VL</given-names></name></person-group><article-title>Poly (ADP-ribose) (PAR)-dependent cell death in neurodegenerative diseases</article-title><source>Int Rev Cell Mol Biol</source><year>2020</year><volume>353</volume><fpage>1</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">32381174</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>S</given-names></name><name><surname>Barber</surname><given-names>R</given-names></name><name><surname>Wilcock</surname><given-names>GK</given-names></name></person-group><article-title>Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease</article-title><source>Brain</source><year>1999</year><fpage>247</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">10071053</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGurk</surname><given-names>L</given-names></name><name><surname>Mojsilovic-Petrovic</surname><given-names>J</given-names></name><name><surname>Van Deerlin</surname><given-names>VM</given-names></name><name><surname>Shorter</surname><given-names>J</given-names></name><name><surname>Kalb</surname><given-names>RG</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><etal/></person-group><article-title>Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis</article-title><source>Acta Neuropathologica Communications</source><year>2018</year><volume>6</volume><fpage>84</fpage><pub-id pub-id-type="pmcid">PMC6114235</pub-id><pub-id pub-id-type="pmid">30157956</pub-id><pub-id pub-id-type="doi">10.1186/s40478-018-0586-1</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kam</surname><given-names>T-I</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Chou</surname><given-names>S-C</given-names></name><name><surname>Karuppagounder</surname><given-names>SS</given-names></name><name><surname>Umanah</surname><given-names>GE</given-names></name><etal/></person-group><article-title>Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson's disease</article-title><source>Science</source><year>2018</year><volume>362</volume><pub-id pub-id-type="pmcid">PMC6431793</pub-id><pub-id pub-id-type="pmid">30385548</pub-id><pub-id pub-id-type="doi">10.1126/science.aat8407</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardinale</surname><given-names>A</given-names></name><name><surname>Paldino</surname><given-names>E</given-names></name><name><surname>Giampà</surname><given-names>C</given-names></name><name><surname>Bernardi</surname><given-names>G</given-names></name><name><surname>Fusco</surname><given-names>FR</given-names></name></person-group><article-title>PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's Disease</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><elocation-id>e0134482</elocation-id><pub-id pub-id-type="pmcid">PMC4529170</pub-id><pub-id pub-id-type="pmid">26252217</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0134482</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paldino</surname><given-names>E</given-names></name><name><surname>Cardinale</surname><given-names>A</given-names></name><name><surname>D'Angelo</surname><given-names>V</given-names></name><name><surname>Sauve</surname><given-names>I</given-names></name><name><surname>Giampà</surname><given-names>C</given-names></name><name><surname>Fusco</surname><given-names>FR</given-names></name></person-group><article-title>Selective Sparing of Striatal Interneurons after Poly (ADP-Ribose) Polymerase 1 Inhibition in the R6/2 Mouse Model of Huntington's Disease</article-title><source>Front Neuroanat</source><year>2017</year><volume>11</volume><fpage>61</fpage><pub-id pub-id-type="pmcid">PMC5539174</pub-id><pub-id pub-id-type="pmid">28824383</pub-id><pub-id pub-id-type="doi">10.3389/fnana.2017.00061</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vis</surname><given-names>JC</given-names></name><name><surname>Schipper</surname><given-names>E</given-names></name><name><surname>de Boer-van Huizen</surname><given-names>RT</given-names></name><name><surname>Verbeek</surname><given-names>MM</given-names></name><name><surname>de Waal</surname><given-names>RMW</given-names></name><name><surname>Wesseling</surname><given-names>P</given-names></name><etal/></person-group><article-title>Expression pattern of apoptosis-related markers in Huntington's disease</article-title><source>Acta Neuropathologica</source><year>2005</year><fpage>321</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">15668790</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thapa</surname><given-names>K</given-names></name><name><surname>Khan</surname><given-names>H</given-names></name><name><surname>Sharma</surname><given-names>U</given-names></name><name><surname>Grewal</surname><given-names>AK</given-names></name><name><surname>Singh</surname><given-names>TG</given-names></name></person-group><article-title>Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases</article-title><source>Life Sci</source><year>2021</year><volume>267</volume><elocation-id>118975</elocation-id><pub-id pub-id-type="pmid">33387580</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>NA</given-names></name><name><surname>Besson</surname><given-names>VC</given-names></name><name><surname>Boulares</surname><given-names>AH</given-names></name><name><surname>Bürkle</surname><given-names>A</given-names></name><name><surname>Chiarugi</surname><given-names>A</given-names></name><name><surname>Clark</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases</article-title><source>Br J Pharmacol</source><year>2018</year><volume>175</volume><fpage>192</fpage><lpage>222</lpage><pub-id pub-id-type="pmcid">PMC5758399</pub-id><pub-id pub-id-type="pmid">28213892</pub-id><pub-id pub-id-type="doi">10.1111/bph.13748</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byrne</surname><given-names>LM</given-names></name><name><surname>Rodrigues</surname><given-names>FB</given-names></name><name><surname>Johnson</surname><given-names>EB</given-names></name><name><surname>Wijeratne</surname><given-names>PA</given-names></name><name><surname>De Vita</surname><given-names>E</given-names></name><name><surname>Alexander</surname><given-names>DC</given-names></name><etal/></person-group><article-title>Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease</article-title><source>Sci Transl Med</source><year>2018</year><volume>10</volume><pub-id pub-id-type="pmid">30209243</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>FB</given-names></name><name><surname>Byrne</surname><given-names>LM</given-names></name><name><surname>Tortelli</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>EB</given-names></name><name><surname>Wijeratne</surname><given-names>PA</given-names></name><name><surname>Arridge</surname><given-names>M</given-names></name><etal/></person-group><article-title>Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease</article-title><source>Sci Transl Med</source><year>2020</year><volume>12</volume><pub-id pub-id-type="pmcid">PMC7611886</pub-id><pub-id pub-id-type="pmid">33328328</pub-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abc2888</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>CL-K</given-names></name><name><surname>Maiuri</surname><given-names>T</given-names></name><name><surname>Bowie</surname><given-names>LE</given-names></name><name><surname>Gotesman</surname><given-names>R</given-names></name><name><surname>Son</surname><given-names>S</given-names></name><name><surname>Falcone</surname><given-names>M</given-names></name><etal/></person-group><article-title>A Patient-Derived Cellular Model for Huntington's Disease Reveals Phenotypes at Clinically Relevant CAG Lengths</article-title><source>Mol Biol Cell</source><year>2018</year><elocation-id>mbcE18090590</elocation-id><pub-id pub-id-type="pmcid">PMC6249865</pub-id><pub-id pub-id-type="pmid">30256717</pub-id><pub-id pub-id-type="doi">10.1091/mbc.E18-09-0590</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holton</surname><given-names>NW</given-names></name><name><surname>Ebenstein</surname><given-names>Y</given-names></name><name><surname>Gassman</surname><given-names>NR</given-names></name></person-group><article-title>Broad spectrum detection of DNA damage by Repair Assisted Damage Detection (RADD)</article-title><source>DNA Repair</source><year>2018</year><volume>66-67</volume><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="pmcid">PMC6375075</pub-id><pub-id pub-id-type="pmid">29723708</pub-id><pub-id pub-id-type="doi">10.1016/j.dnarep.2018.04.007</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>DI</given-names></name><name><surname>Durant</surname><given-names>S</given-names></name><name><surname>Eckersley</surname><given-names>K</given-names></name><name><surname>Fairweather</surname><given-names>E</given-names></name><name><surname>Griffiths</surname><given-names>LA</given-names></name><name><surname>Hamilton</surname><given-names>N</given-names></name><etal/></person-group><article-title>An assay to measure poly(ADP ribose) glycohydrolase (PARG) activity in cells</article-title><source>F1000Res</source><year>2016</year><volume>5</volume><fpage>736</fpage><pub-id pub-id-type="pmcid">PMC4995692</pub-id><pub-id pub-id-type="pmid">27610220</pub-id><pub-id pub-id-type="doi">10.12688/f1000research.8463.2</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanev</surname><given-names>P-B</given-names></name><name><surname>Varhoshkova</surname><given-names>S</given-names></name><name><surname>Georgieva</surname><given-names>I</given-names></name><name><surname>Lukarska</surname><given-names>M</given-names></name><name><surname>Kirova</surname><given-names>D</given-names></name><name><surname>Danovski</surname><given-names>G</given-names></name><etal/></person-group><article-title>A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells</article-title><source>Cell Rep</source><year>2024</year><volume>43</volume><elocation-id>114234</elocation-id><pub-id pub-id-type="pmid">38758646</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>H</given-names></name><name><surname>Bhardwaj</surname><given-names>A</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Fijen</surname><given-names>C</given-names></name><name><surname>Ephstein</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>A two-step mechanism governing PARP1-DNA retention by PARP inhibitors</article-title><source>Sci Adv</source><year>2022</year><volume>8</volume><elocation-id>eabq0414</elocation-id><pub-id pub-id-type="pmcid">PMC9451145</pub-id><pub-id pub-id-type="pmid">36070389</pub-id><pub-id pub-id-type="doi">10.1126/sciadv.abq0414</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caldecott</surname><given-names>KW</given-names></name></person-group><article-title>XRCC1 protein; Form and function</article-title><source>DNA Repair</source><year>2019</year><volume>81</volume><pub-id pub-id-type="pmid">31324530</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagné</surname><given-names>J-P</given-names></name><name><surname>Isabelle</surname><given-names>M</given-names></name><name><surname>Lo</surname><given-names>KS</given-names></name><name><surname>Bourassa</surname><given-names>S</given-names></name><name><surname>Hendzel</surname><given-names>MJ</given-names></name><name><surname>Dawson</surname><given-names>VL</given-names></name><etal/></person-group><article-title>Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes</article-title><source>Nucleic Acids Res</source><year>2008</year><volume>36</volume><fpage>6959</fpage><lpage>6976</lpage><pub-id pub-id-type="pmcid">PMC2602769</pub-id><pub-id pub-id-type="pmid">18981049</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkn771</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name></person-group><article-title>Site-specific characterization of the Asp- and Glu-ADP-ribosylated proteome</article-title><source>Nat Methods</source><year>2013</year><volume>10</volume><fpage>981</fpage><lpage>984</lpage><pub-id pub-id-type="pmid">23955771</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jungmichel</surname><given-names>S</given-names></name><name><surname>Rosenthal</surname><given-names>F</given-names></name><name><surname>Altmeyer</surname><given-names>M</given-names></name><name><surname>Lukas</surname><given-names>J</given-names></name><name><surname>Hottiger</surname><given-names>MO</given-names></name><name><surname>Nielsen</surname><given-names>ML</given-names></name></person-group><article-title>Proteome-wide identification of poly(ADP-Ribosyl)ation targets in different genotoxic stress responses</article-title><source>Mol Cell</source><year>2013</year><volume>52</volume><fpage>272</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">24055347</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanai</surname><given-names>Y</given-names></name></person-group><article-title>Overview on poly(ADP-ribose) immuno-biomedicine and future prospects</article-title><source>Proc Jpn Acad Ser B Phys Biol Sci</source><year>2016</year><volume>92</volume><fpage>222</fpage><pub-id pub-id-type="pmcid">PMC5114291</pub-id><pub-id pub-id-type="pmid">27477457</pub-id><pub-id pub-id-type="doi">10.2183/pjab.92.222</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanai</surname><given-names>Y</given-names></name><name><surname>Tanuma</surname><given-names>S</given-names></name><name><surname>Sugimura</surname><given-names>T</given-names></name></person-group><article-title>Immunofluorescent staining of poly(ADP-ribose) in situ in HeLa cell chromosomes in the M phase</article-title><source>Proc Natl Acad Sci U S A</source><year>1981</year><volume>78</volume><fpage>2801</fpage><pub-id pub-id-type="pmcid">PMC319445</pub-id><pub-id pub-id-type="pmid">6265913</pub-id><pub-id pub-id-type="doi">10.1073/pnas.78.5.2801</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atwal</surname><given-names>RS</given-names></name><name><surname>Desmond</surname><given-names>CR</given-names></name><name><surname>Caron</surname><given-names>N</given-names></name><name><surname>Maiuri</surname><given-names>T</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Sipione</surname><given-names>S</given-names></name><etal/></person-group><article-title>Kinase inhibitors modulate huntingtin cell localization and toxicity</article-title><source>Nat Chem Biol</source><year>2011</year><volume>7</volume><fpage>453</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">21623356</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godin</surname><given-names>JD</given-names></name><name><surname>Colombo</surname><given-names>K</given-names></name><name><surname>Molina-Calavita</surname><given-names>M</given-names></name><name><surname>Keryer</surname><given-names>G</given-names></name><name><surname>Zala</surname><given-names>D</given-names></name><name><surname>Charrin</surname><given-names>BC</given-names></name><etal/></person-group><article-title>Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis</article-title><source>Neuron</source><year>2010</year><volume>67</volume><fpage>392</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">20696378</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pleschke</surname><given-names>JM</given-names></name><name><surname>Kleczkowska</surname><given-names>HE</given-names></name><name><surname>Strohm</surname><given-names>M</given-names></name><name><surname>Althaus</surname><given-names>FR</given-names></name></person-group><article-title>Poly (ADP-ribose) binds to specific domains in DNA damage checkpoint proteins</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>40974</fpage><lpage>40980</lpage><pub-id pub-id-type="pmid">11016934</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagné</surname><given-names>J-P</given-names></name><name><surname>Hunter</surname><given-names>JM</given-names></name><name><surname>Labrecque</surname><given-names>B</given-names></name><name><surname>Chabot</surname><given-names>B</given-names></name><name><surname>Poirier</surname><given-names>GG</given-names></name></person-group><article-title>A proteomic approach to the identification of heterogeneous nuclear ribonucleoproteins as a new family of poly(ADP-ribose)-binding proteins</article-title><source>Biochem J</source><year>2003</year><volume>371</volume><fpage>331</fpage><lpage>340</lpage><pub-id pub-id-type="pmcid">PMC1223283</pub-id><pub-id pub-id-type="pmid">12517304</pub-id><pub-id pub-id-type="doi">10.1042/BJ20021675</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname><given-names>RJ</given-names></name><name><surname>Deme</surname><given-names>JC</given-names></name><name><surname>Hevler</surname><given-names>JF</given-names></name><name><surname>Tamara</surname><given-names>S</given-names></name><name><surname>Lemak</surname><given-names>A</given-names></name><name><surname>Cantle</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Huntingtin structure is orchestrated by HAP40 and shows a polyglutamine expansion-specific interaction with exon 1</article-title><source>Communications Biology</source><year>2021</year><volume>4</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="pmcid">PMC8654980</pub-id><pub-id pub-id-type="pmid">34880419</pub-id><pub-id pub-id-type="doi">10.1038/s42003-021-02895-4</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Chaban</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>C</given-names></name><name><surname>Pan</surname><given-names>B</given-names></name><etal/></person-group><article-title>Structural insights into the activation of ATM kinase</article-title><source>Cell Res</source><year>2019</year><volume>29</volume><fpage>683</fpage><lpage>685</lpage><pub-id pub-id-type="pmcid">PMC6796860</pub-id><pub-id pub-id-type="pmid">31320732</pub-id><pub-id pub-id-type="doi">10.1038/s41422-019-0205-0</pub-id></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reber</surname><given-names>JM</given-names></name><name><surname>Mangerich</surname><given-names>A</given-names></name></person-group><article-title>Why structure and chain length matter: on the biological significance underlying the structural heterogeneity of poly(ADP-ribose)</article-title><source>Nucleic Acids Res</source><year>2021</year><volume>49</volume><fpage>8432</fpage><lpage>8448</lpage><pub-id pub-id-type="pmcid">PMC8421145</pub-id><pub-id pub-id-type="pmid">34302489</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkab618</pub-id></element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alteen</surname><given-names>MG</given-names></name><name><surname>Deme</surname><given-names>JC</given-names></name><name><surname>Alvarez</surname><given-names>CP</given-names></name><name><surname>Loppnau</surname><given-names>P</given-names></name><name><surname>Hutchinson</surname><given-names>A</given-names></name><name><surname>Seitova</surname><given-names>A</given-names></name><etal/></person-group><article-title>Expanding the Huntingtons disease research toolbox; validated huntingtin subdomain constructs for biochemical and structural investigation of the huntingtin protein</article-title><source>bioRxiv</source><year>2022</year><elocation-id>2022.11.21.516512</elocation-id><pub-id pub-id-type="doi">10.1101/2022.11.21.516512</pub-id></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naumenko</surname><given-names>KN</given-names></name><name><surname>Sukhanova</surname><given-names>MV</given-names></name><name><surname>Hamon</surname><given-names>L</given-names></name><name><surname>Kurgina</surname><given-names>TA</given-names></name><name><surname>Anarbaev</surname><given-names>RO</given-names></name><name><surname>Mangerich</surname><given-names>A</given-names></name><etal/></person-group><article-title>The C-Terminal Domain of Y-Box Binding Protein 1 Exhibits Structure-Specific Binding to Poly(ADP-Ribose), Which Regulates PARP1 Activity</article-title><source>Frontiers in Cell and Developmental Biology</source><year>2022</year><volume>10</volume><pub-id pub-id-type="pmcid">PMC9253770</pub-id><pub-id pub-id-type="pmid">35800891</pub-id><pub-id pub-id-type="doi">10.3389/fcell.2022.831741</pub-id></element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sukhanova</surname><given-names>MV</given-names></name><name><surname>Abrakhi</surname><given-names>S</given-names></name><name><surname>Joshi</surname><given-names>V</given-names></name><name><surname>Pastre</surname><given-names>D</given-names></name><name><surname>Kutuzov</surname><given-names>MM</given-names></name><name><surname>Anarbaev</surname><given-names>RO</given-names></name><etal/></person-group><article-title>Single molecule detection of PARP1 and PARP2 interaction with DNA strand breaks and their poly(ADP-ribosyl)ation using high-resolution AFM imaging</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>44</volume><fpage>e60</fpage><pub-id pub-id-type="pmcid">PMC4824093</pub-id><pub-id pub-id-type="pmid">26673720</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkv1476</pub-id></element-citation></ref><ref id="R79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naumenko</surname><given-names>KN</given-names></name><name><surname>Sukhanova</surname><given-names>MV</given-names></name><name><surname>Hamon</surname><given-names>L</given-names></name><name><surname>Kurgina</surname><given-names>TA</given-names></name><name><surname>Alemasova</surname><given-names>EE</given-names></name><name><surname>Kutuzov</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Regulation of Poly(ADP-Ribose) Polymerase 1 Activity by Y-Box-Binding Protein 1</article-title><source>Biomolecules</source><year>2020</year><volume>10</volume><elocation-id>1325</elocation-id><pub-id pub-id-type="pmcid">PMC7565162</pub-id><pub-id pub-id-type="pmid">32947956</pub-id><pub-id pub-id-type="doi">10.3390/biom10091325</pub-id></element-citation></ref><ref id="R80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saudou</surname><given-names>F</given-names></name><name><surname>Humbert</surname><given-names>S</given-names></name></person-group><article-title>The Biology of Huntingtin</article-title><source>Neuron</source><year>2016</year><volume>89</volume><fpage>910</fpage><lpage>926</lpage><pub-id pub-id-type="pmid">26938440</pub-id></element-citation></ref><ref id="R81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desmond</surname><given-names>CR</given-names></name><name><surname>Atwal</surname><given-names>RS</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Truant</surname><given-names>R</given-names></name></person-group><article-title>Identification of a karyopherin β1/β2 proline-tyrosine nuclear localization signal in huntingtin protein</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><fpage>39626</fpage><lpage>39633</lpage><pub-id pub-id-type="pmcid">PMC3501053</pub-id><pub-id pub-id-type="pmid">23012356</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M112.412379</pub-id></element-citation></ref><ref id="R82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Taylor</surname><given-names>J</given-names></name><name><surname>Vandelft</surname><given-names>M</given-names></name><name><surname>Truant</surname><given-names>R</given-names></name></person-group><article-title>Huntingtin contains a highly conserved nuclear export signal</article-title><source>Hum Mol Genet</source><year>2003</year><volume>12</volume><fpage>1393</fpage><lpage>1403</lpage><pub-id pub-id-type="pmid">12783847</pub-id></element-citation></ref><ref id="R83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maiuri</surname><given-names>T</given-names></name><name><surname>Woloshansky</surname><given-names>T</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Truant</surname><given-names>R</given-names></name></person-group><article-title>The huntingtin N17 domain is a multifunctional CRM1 and Ran-dependent nuclear and cilial export signal</article-title><source>Hum Mol Genet</source><year>2013</year><volume>22</volume><fpage>1383</fpage><lpage>1394</lpage><pub-id pub-id-type="pmcid">PMC3596850</pub-id><pub-id pub-id-type="pmid">23297360</pub-id><pub-id pub-id-type="doi">10.1093/hmg/dds554</pub-id></element-citation></ref><ref id="R84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atwal</surname><given-names>RS</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Pinchev</surname><given-names>D</given-names></name><name><surname>Taylor</surname><given-names>J</given-names></name><name><surname>Epand</surname><given-names>RM</given-names></name><name><surname>Truant</surname><given-names>R</given-names></name></person-group><article-title>Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity</article-title><source>Hum Mol Genet</source><year>2007</year><volume>16</volume><fpage>2600</fpage><lpage>2615</lpage><pub-id pub-id-type="pmid">17704510</pub-id></element-citation></ref><ref id="R85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiGiovanni</surname><given-names>LF</given-names></name><name><surname>Mocle</surname><given-names>AJ</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Truant</surname><given-names>R</given-names></name></person-group><article-title>Huntingtin N17 domain is a reactive oxygen species sensor regulating huntingtin phosphorylation and localization</article-title><source>Hum Mol Genet</source><year>2016</year><pub-id pub-id-type="pmcid">PMC5291230</pub-id><pub-id pub-id-type="pmid">27466181</pub-id><pub-id pub-id-type="doi">10.1093/hmg/ddw234</pub-id></element-citation></ref><ref id="R86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maiuri</surname><given-names>T</given-names></name><name><surname>Bowie</surname><given-names>LE</given-names></name><name><surname>Truant</surname><given-names>R</given-names></name></person-group><article-title>DNA Repair Signaling of Huntingtin: The Next Link Between Late-Onset Neurodegenerative Disease and Oxidative DNA Damage</article-title><source>DNA Cell Biol</source><year>2019</year><volume>38</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">30481056</pub-id></element-citation></ref><ref id="R87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slade</surname><given-names>D</given-names></name></person-group><article-title>PARP and PARG inhibitors in cancer treatment</article-title><source>Genes Dev</source><year>2020</year><volume>34</volume><fpage>360</fpage><lpage>394</lpage><pub-id pub-id-type="pmcid">PMC7050487</pub-id><pub-id pub-id-type="pmid">32029455</pub-id><pub-id pub-id-type="doi">10.1101/gad.334516.119</pub-id></element-citation></ref><ref id="R88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byrne</surname><given-names>LM</given-names></name><name><surname>Wild</surname><given-names>EJ</given-names></name></person-group><article-title>Cerebrospinal Fluid Biomarkers for Huntington's Disease</article-title><source>J Huntingtons Dis</source><year>2016</year><volume>5</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">27031730</pub-id></element-citation></ref><ref id="R89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNulty</surname><given-names>P</given-names></name><name><surname>Pilcher</surname><given-names>R</given-names></name><name><surname>Ramesh</surname><given-names>R</given-names></name><name><surname>Necuiniate</surname><given-names>R</given-names></name><name><surname>Hughes</surname><given-names>A</given-names></name><name><surname>Farewell</surname><given-names>D</given-names></name><etal/></person-group><article-title>Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study</article-title><source>J Huntingtons Dis</source><year>2018</year><volume>7</volume><fpage>209</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">30103338</pub-id></element-citation></ref><ref id="R90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubinsztein</surname><given-names>DC</given-names></name><name><surname>Amos</surname><given-names>W</given-names></name><name><surname>Leggo</surname><given-names>J</given-names></name><name><surname>Goodburn</surname><given-names>S</given-names></name><name><surname>Ramesar</surname><given-names>RS</given-names></name><name><surname>Old</surname><given-names>J</given-names></name><etal/></person-group><article-title>Mutational bias provides a model for the evolution of Huntington's disease and predicts a general increase in disease prevalence</article-title><source>Nat Genet</source><year>1994</year><volume>7</volume><fpage>525</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">7951324</pub-id></element-citation></ref><ref id="R91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landwehrmeyer</surname><given-names>GB</given-names></name><name><surname>Fitzer-Attas</surname><given-names>CJ</given-names></name><name><surname>Giuliano</surname><given-names>JD</given-names></name><name><surname>Gonçalves</surname><given-names>N</given-names></name><name><surname>Anderson</surname><given-names>KE</given-names></name><name><surname>Cardoso</surname><given-names>F</given-names></name><etal/></person-group><article-title>Data Analytics from Enroll-HD, a Global Clinical Research Platform for Huntington's Disease</article-title><source>Mov Disord Clin Pract</source><year>2017</year><volume>4</volume><fpage>212</fpage><lpage>224</lpage><pub-id pub-id-type="pmcid">PMC6174428</pub-id><pub-id pub-id-type="pmid">30363395</pub-id><pub-id pub-id-type="doi">10.1002/mdc3.12388</pub-id></element-citation></ref><ref id="R92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trettel</surname><given-names>F</given-names></name><name><surname>Rigamonti</surname><given-names>D</given-names></name><name><surname>Hilditch-Maguire</surname><given-names>P</given-names></name><name><surname>Wheeler</surname><given-names>VC</given-names></name><name><surname>Sharp</surname><given-names>AH</given-names></name><name><surname>Persichetti</surname><given-names>F</given-names></name><etal/></person-group><article-title>Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells</article-title><source>Hum Mol Genet</source><year>2000</year><volume>9</volume><fpage>2799</fpage><lpage>2809</lpage><pub-id pub-id-type="pmid">11092756</pub-id></element-citation></ref><ref id="R93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith-Geater</surname><given-names>C</given-names></name><name><surname>Hernandez</surname><given-names>SJ</given-names></name><name><surname>Lim</surname><given-names>RG</given-names></name><name><surname>Adam</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Stocksdale</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Aberrant Development Corrected in Adult-Onset Huntington's Disease iPSC-Derived Neuronal Cultures via WNT Signaling Modulation</article-title><source>Stem Cell Reports</source><year>2020</year><volume>14</volume><fpage>406</fpage><lpage>419</lpage><pub-id pub-id-type="pmcid">PMC7066322</pub-id><pub-id pub-id-type="pmid">32109367</pub-id><pub-id pub-id-type="doi">10.1016/j.stemcr.2020.01.015</pub-id></element-citation></ref><ref id="R94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goss</surname><given-names>S</given-names></name><name><surname>Bazan</surname><given-names>CB</given-names></name><name><surname>Neuman</surname><given-names>K</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Begeja</surname><given-names>N</given-names></name><name><surname>Suart</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Mod3D: A low-cost, flexible modular system of live-cell microscopy chambers and holders</article-title><source>PLoS One</source><year>2022</year><volume>17</volume><elocation-id>e0269345</elocation-id><pub-id pub-id-type="pmcid">PMC9165904</pub-id><pub-id pub-id-type="pmid">35657927</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0269345</pub-id></element-citation></ref><ref id="R95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carpenter</surname><given-names>AE</given-names></name><name><surname>Jones</surname><given-names>TR</given-names></name><name><surname>Lamprecht</surname><given-names>MR</given-names></name><name><surname>Clarke</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>IH</given-names></name><name><surname>Friman</surname><given-names>O</given-names></name><etal/></person-group><article-title>CellProfiler: image analysis software for identifying and quantifying cell phenotypes</article-title><source>Genome Biol</source><year>2006</year><volume>7</volume><fpage>R100</fpage><pub-id pub-id-type="pmcid">PMC1794559</pub-id><pub-id pub-id-type="pmid">17076895</pub-id><pub-id pub-id-type="doi">10.1186/gb-2006-7-10-r100</pub-id></element-citation></ref><ref id="R96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname><given-names>RJ</given-names></name><name><surname>Loppnau</surname><given-names>P</given-names></name><name><surname>Ackloo</surname><given-names>S</given-names></name><name><surname>Lemak</surname><given-names>A</given-names></name><name><surname>Hutchinson</surname><given-names>A</given-names></name><name><surname>Hunt</surname><given-names>B</given-names></name><etal/></person-group><article-title>Design and characterization of mutant and wildtype huntingtin proteins produced from a toolkit of scalable eukaryotic expression systems</article-title><source>J Biol Chem</source><year>2019</year><volume>294</volume><fpage>6986</fpage><lpage>7001</lpage><pub-id pub-id-type="pmcid">PMC6497952</pub-id><pub-id pub-id-type="pmid">30842263</pub-id><pub-id pub-id-type="doi">10.1074/jbc.RA118.007204</pub-id></element-citation></ref><ref id="R97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ando</surname><given-names>Y</given-names></name><name><surname>Elkayam</surname><given-names>E</given-names></name><name><surname>McPherson</surname><given-names>RL</given-names></name><name><surname>Dasovich</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>S-J</given-names></name><name><surname>Voorneveld</surname><given-names>J</given-names></name><etal/></person-group><article-title>ELTA: Enzymatic Labeling of Terminal ADP-Ribose</article-title><source>Mol Cell</source><year>2019</year><volume>73</volume><fpage>845</fpage><lpage>856</lpage><elocation-id>e5</elocation-id><pub-id pub-id-type="pmcid">PMC6629254</pub-id><pub-id pub-id-type="pmid">30712989</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2018.12.022</pub-id></element-citation></ref><ref id="R98"><label>98</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pallant</surname><given-names>J</given-names></name></person-group><source>SPSS survival manual: A step by step guide to data analysis using IBM SPSS</source><date-in-citation>cited 11 Oct 2022</date-in-citation><comment>/spss-survival-manual-julie-pallant</comment><pub-id pub-id-type="doi">10.4324/9781003117452</pub-id></element-citation></ref></ref-list></back><floats-group><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>Significance statement</title></caption><p>A consensus on dysfunctional DNA repair has emerged in neurodegenerative disease research, with elevated poly ADP-ribose (PAR) signaling more recently implicated. In contrast, we have identified a deficient PAR response in Huntington's disease (HD) patient spinal fluid samples and cells. This may be explained by the inability of huntingtin protein bearing the HD-causing mutation to stimulate production of PAR the way the wild type protein does. Since drugs that target PAR production and degradation have already been developed, these findings present an exciting avenue for therapeutic intervention for HD.</p></boxed-text><fig id="F1" position="float"><label>Figure 1</label><caption><title>PAR levels are reduced in premanifest and manifest HD patient CSF</title><p>CSF samples from control, premanifest HD, and manifest HD subjects were blinded and analyzed for PAR levels by ELISA. Group comparisons were assessed using multiple regression with post-hoc Wald tests. *Survives Bonferroni correction for multiple comparisons.</p></caption><graphic xlink:href="EMS157695-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>The PAR response is deficient in HD cells</title><p><bold>A:</bold> iPSC-derived neurons were fixed and stained with neuronal marker Map2 (red) and MABE1031 PAR detection reagent (green). Nuclear PAR intensity in Map2-positive cells was measured using CellProfiler. Data from six (CTR Q18 and HD Q53) or four (JHD Q77) differentiation replicates are shown (n=100-300 nuclei per cell line). Results were analyzed by Kruskal-Wallis test and corrected for multiple comparisons using Dunn's test. Error bars: SEM. <bold>B:</bold> hTERT-immortalized fibroblasts from healthy control (TruHD-Q21Q18) and HD patients (TruHD-Q43Q17 and TruHD-Q50Q40) were treated with 100 mM KBrO<sub>3</sub> for 30 min followed by Repair Assisted Damage Detection (RADD) to detect DNA damage, and co-staining with MABE1031 PAR detection reagent. Representative images of TruHD-Q21Q18 cells are shown. Nuclear RADD and PAR intensity were measured using CellProfiler, mean intensity recorded for each image (18 images per condition; &gt;500 cells), and values normalized to the control condition. Data from three independent experiments is shown. Results were analyzed by two-way ANOVA and corrected for multiple comparisons using Tukey's test. Error bars: SEM. Scale bars: 50 microns.</p></caption><graphic xlink:href="EMS157695-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>PARP1/2 activity is higher in the presence of wild type huntingtin</title><p>Fibroblasts were pre-treated with increasing doses of PDD00017273 <bold>(A)</bold> or veliparib <bold>(B)</bold> for 30 min followed by 100 mM KBrO<sub>3</sub> for 30 min in the presence of inhibitor. Veliparib dose response was carried out in the presence of 5 μM PARG inhibitor to enable pan-ADP-ribose detection by MABE1016. EC<sub>50</sub> and IC<sub>50</sub> values were calculated from nuclear PAR staining intensity (10-12 images per condition; &gt;800 cells) using GraphPad Prism. Error bars = SEM for 4 (PARG inhibitor) or 8 (veliparib) experiments. **** p&lt;0.0001 (Brown-Forsythe and Welch ANOVA tests). <bold>C:</bold> 10 fmol recombinant PARP1 was incubated with the indicated amounts of recombinant HTT-HAP40 for 2 hours at 30°C. Reactions were separated by SDS-PAGE and immunoblotted with MABE1016 pan-ADP-ribose detection reagent. Signal intensities were quantified using ImageJ. Values from three (HTT-HAP40 Q54) or four (HTT-HAP40 Q23) experiments are shown.</p></caption><graphic xlink:href="EMS157695-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Huntingtin interacts with PARylated proteins</title><p><bold>A:</bold> Degree of overlap between huntingtin interacting proteins and a list of PARylated proteins compiled from three independent studies, with Fisher's exact test for statistical significance. <bold>B:</bold> RPE1 cells were treated with 400 μM H<sub>2</sub>O<sub>2</sub> in HBSS for 10 min and proteins crosslinked with 1% PFA prior to lysis. Huntingtin was immunoprecipitated with EPR5526 and associated proteins separated by SDS-PAGE and immunoblotted with the indicated antibodies. PARylated proteins of various sizes in the whole cell lysate (input) and anti-huntingtin immunoprecipitate (HTT IP) were detected with pan ADP-ribose detection reagent (MABE1016) followed by HRP-conjugated anti-rabbit secondary antibody. Rabbit IgG signal from the anti-huntingtin immunoprecipitating antibody (EPR5526) was visible upon incubation with secondary anti-rabbit antibody. Results representative of four experiments. <bold>C:</bold> RPE1 cells were treated with either 10 μM PDD00017273 PARG inhibitor (top panel) or 1 μM talazoparib PARP1/2 inhibitor (bottom panel) for 40 min prior to methanol fixation and immunofluorescence against huntingtin phosphorylated at residues S13 and S16 within the N17 domain (Huntingtin phospho-N17, yellow), and PARP1 (PARP1, magenta), followed by counterstaining with Hoechst (DNA, cyan). Image representative of all mitotic cells observed (n &gt; 10 cells from two independent experiments). Scale bar: 10 μm.</p></caption><graphic xlink:href="EMS157695-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>Huntingtin has a PAR-binding motif (PBM)</title><p><bold>A:</bold> Known PBMs compared to putative PBMs in huntingtin. PBM-X is not solvent-accessible and was not analyzed further. b: basic, h: hydrophobic, x: any amino acid. Critical basic amino acids depicted in black boxes. <bold>B:</bold> Peptides were slot-blotted onto nitrocellulose then overlaid with 0.2 μM PAR polymer. After washing, anti-PAR western was performed with pan ADP-ribose detection reagent MABE1016. <bold>C:</bold> Left: high resolution cryoEM model of huntingtin-HAP40 complex (PDB - 6X9O) shown in surface representation with huntingtin in gray, HAP40 in pink, and the PAR-binding motif in orange. Right: PAR-binding motif shown in stick representation in orange. Positively charged K1790, R1795 and R1796 residues are surface exposed.</p></caption><graphic xlink:href="EMS157695-f005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><title>Huntingtin directly binds PAR</title><p><bold>A:</bold> Fluorescence polarization assays using FAM-labeled 11-mer or 26-mer PAR and purified HTT-HAP40 Q23. Results for 2 experiments are shown. Error bars = SD. <bold>B:</bold> Fluorescence polarization assays using FAM-labeled 26-mer PAR and 10 μM of the indicated subdomains of huntingtin. Reactions were carried out with 3-4 intra-assay replicates. Results for 3 experiments were analyzed by one-way ANOVA and corrected for multiple comparisons by Kruskal-Wallis test (***p&lt;0.0005, ****p&lt;0.0001). <bold>C:</bold> Recombinant HTT-HAP40 was added to PARP1 activity assays and reactions were deposited on mica and visualized by atomic force microscopy. 2D (left) and 3D (right) images are shown with corresponding colour scale for PARylated PARP1 (2.0 nm) or PARylated PARP1 with HTT-HAP40 (10.0 nm).</p></caption><graphic xlink:href="EMS157695-f006"/></fig></floats-group></article>